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Abstract 1 
Diabetes is the leading cause of end stage renal disease. Despite evidence for a substantial heritability of 2 
diabetic kidney disease, efforts to identify genetic susceptibility variants have had limited success. We 3 
extended previous efforts in three dimensions, examining a more comprehensive set of genetic variants in 4 
larger numbers of subjects with type 1 diabetes characterized for a wider range of cross-sectional diabetic 5 
kidney disease phenotypes. In 2,843 subjects, we estimated that the heritability
 
of diabetic kidney disease was 6 
35% (p=6x10
-3
). Genome-wide association analysis and replication in 12,540 individuals identified no single 7 
variants reaching stringent levels of significance and, despite excellent power, provided little independent 8 
confirmation of previously published associated variants. Whole exome sequencing in 997 subjects failed to 9 
identify any large-effect coding alleles of lower frequency influencing the risk of diabetic kidney disease. 10 
However, sets of alleles increasing body mass index (p=2.2×10
-5
) and the risk of type 2 diabetes (p=6.1x10
-4
) 11 
were associated with the risk of diabetic kidney disease. We also found genome-wide genetic correlation 12 
between diabetic kidney disease and failure at smoking cessation (p=1.1×10
-4
). Pathway analysis implicated 13 
ascorbate and aldarate metabolism (p=9×10
-6
), and pentose and glucuronate interconversions (p=3×10
-6
) in 14 
pathogenesis of diabetic kidney disease.  15 
These data provide further evidence for the role of genetic factors influencing diabetic kidney disease in those 16 
with type 1 diabetes and highlight some key pathways that may be responsible. Altogether these results reveal 17 
important biology behind the major cause of kidney disease.  18 
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Introduction 
Diabetes is the leading cause of end stage renal disease (ESRD).
1
 Among the patients with type 1 diabetes 
(T1D), as many as one third develop serious renal complications,
2
 characterized by increasing urinary albumin 
excretion rates (AER) and decreasing kidney function, measured by estimated glomerular filtration rate (eGFR), 
with 10%-20% of the subjects progressing to ESRD.
3,4
 In the vast majority of patients with T1D, renal 
complications reflect the condition of diabetic nephropathy,
5
 though we use the term diabetic kidney disease 
(DKD) here to reflect the fact that not all have histological evidence of DN. While DKD is associated with high 
risk of cardiovascular disease
6
 and premature mortality,
7
 those who manage to avoid DKD have much better 
prognosis with survival rates comparable to subjects without diabetes.
7
 The treatment of DKD, primarily relying 
on the control of blood glucose levels and on the use of anti-hypertensive medication, can only retard disease 
progression rather than restore kidney function or efficiently prevent ESRD. This highlights the need for a 
better mechanistic understanding of DKD which would provide improved therapeutic targets and biomarkers of 
progression, both of which are expected to lead to improved personalization of care.  
Family studies have shown familial clustering of DKD with a 2.1 – 2.3 fold increased risk of DKD in T1D siblings 
of probands with DKD.
8-10
 There is also evidence for shared genetic background between DKD and other 
diseases: the parents of the subjects with T1D and DKD have more type 2 diabetes (T2D) and cardiovascular 
disease
11-13
. Despite evidence for genetic predisposition, few compelling signals have been identified for DKD. 
Positive reports of association with a range of candidate genes have generally failed to find support in larger 
analyses of independent samples,
14
 and only a few loci have been identified with genome-wide association 
studies (GWAS)
15-17
. In contrast, there have been a number of a robust, replicated associations described for 
chronic kidney disease (CKD) in the general population
18-20
. However, evidence that these variants influence 
predisposition to CKD in diabetes is mixed
15,20
.  
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The limited success of GWAS on DKD thus far may be due to multiple factors: relatively small sample sizes (in 
the thousands at the discovery stage); imprecise and variable diagnostics or phenotypic heterogeneity; and a 
focus on common variants (minor allele frequency [MAF] ≥5%), that neglects the possible contribution of lower 
frequency variants to DKD predisposition. In other complex traits, such as schizophrenia, initial challenges in 
identifying robust association signals have been overcome as sample sizes have increased
21,22
. 
To overcome the limitations of previous studies in DKD, in this study we: increased sample size through GWAS 
meta-analysis; analysed a range of phenotypic comparisons that encompass different stages and severity of 
DKD in subjects with T1D; and extended the genome-wide association screen from common variants to lower 
frequency coding variants through whole exome sequencing (WES).  
 
Results 
DKD traits are heritable 
Since no comprehensive evaluation of heritability exists for the various stages of DKD, we estimated the 
narrow-sense, “chip” heritability (i.e. the proportion of phenotypic variance explained by genome-wide SNPs; 
h
2
) for the seven applied DKD phenotypic comparisons (Figure 1) in the context of T1D using data from the 
largest included GWAS study, the Finnish Diabetic Nephropathy (FinnDiane) Study
23
. Heritability estimates 
varied greatly across the comparisons (Figure 2): For the primary, ‘combined DKD’ phenotypic comparison 
(micro- or macroalbuminuria or ESRD versus normal AER), h
2
 was 35% (p=6x10
-3
; Supplemental Table 1). The 
highest value, h
2
 =59%, was obtained for ‘CKD+DKD’ (those with both CKD and DKD assigned as cases, and 
those with no CKD and no DKD as controls; p=1x10
-3
). Other late stage phenotype definitions also yielded high 
estimates of heritability, e.g. 47% for ‘ESRD versus no DKD’ (p=3x10
-3
). When we included gender, diabetes 
duration, and age at diabetes diagnosis as covariates, the proportion of the remaining phenotypic variance 
explained by the genotyped SNPs increased for each phenotypic comparison, e.g. from 35 % to 50% for 
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‘combined DKD’ (p=2.5×10
-4
). The estimates represent lower limits for the total heritability of DKD traits, as the 
method considers only those causal variants captured by the variants genotyped on the array.  
 
GWAS 
The GWAS discovery stage included 3,135-5,156 subjects with T1D, depending on phenotypic comparison 
(Supplemental Figure 1), from four studies: FinnDiane
23
, the EURODIAB Family Study
24
, the Scania Diabetes 
Registry (SDR)
25
, and the UK Nephropathy Family Study and Oxford Regional Prospective Study (NFS-ORPS/ 
Cambridge)
26,27
 (Table 1, Supplemental Tables 2 and 3). 
With 2,563 T1D DKD cases and 2,593 T1D non-DKD controls for the ‘combined DKD’ phenotype in the discovery 
cohorts, we estimated >80% statistical power to detect variants with MAF≥10% and allelic odds ratios (OR) 
≥1.55 at genome-wide significance (p<5×10
-8
; Supplemental Table 4). Results from meta-analyses were well 
calibrated (genomic control [λGC] 1.01-1.05; Supplemental Figure 2) but showed little deviation from the null 
with no SNP reaching p<5×10
-8
 (no adjustment for multiple phenotypes). Across seven DKD case-control 
comparisons, a total of 101 regional lead SNPs reached a suggestive p-value of <5×10
-6
 in at least one analysis 
(Supplemental Table 5). These 101 associations were tested for all DKD phenotypes available in the various 
stage 2 samples (Supplemental Tables 2 and 3), though meta-analysis results were only compiled across data 
for equivalent phenotypes. The two-stage design provided ≥80% power for the primary ‘combined DKD’ 
comparison to reach p<5×10
-8
 for variants with an OR≥1.47 and MAF≥10% (Supplemental Table 6).  
In the joint meta-analysis  of stage 1 and 2 samples, no SNP reached p<5×10
-8
, while three achieved p<1×10
-6
, 
all for the ESRD based case definitions: rs1989248 near CNTNAP2, rs61277444 in PTPN13, and rs7562121 in 
AFF3 (Supplemental Figure 3, Supplemental Table 5). We also identified rs72809865 near NRG3 for further 
replication based on nominal replication (p=0.047) for ‘combined DKD’ in stage 2. These four SNPs were 
examined in 1,087 additional subjects using de novo genotyping (Stage 3), though direct genotyping was 
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unsuccessful for rs1989248 (near CNTNAP2). After the joint analysis of stage 1-3 results, the association at 
rs7562121 in AFF3 remained suggestive (p<1×10
-6
; Table 2).  
Rs7562121 in AFF3 is in moderate linkage disequilibrium (LD) with rs7583877 (r
2
=0.67, D’= 0.94), the variant 
previously associated with ESRD in T1D
15
. Conditional analysis showed that both SNPs represent the same 
signal (Supplemental Table 7). However, the present study cannot be considered replication of previous reports 
because of substantial overlap of study samples. Analysis in non-overlapping samples (222 ESRD cases, 1,640 
non-ESRD controls) provided no independent corroboration of the AFF3 association (OR=1.02, p=0.82).  
The substantial heritability captured by SNPs on the genotyping array, and the failure to detect genome-wide 
significant signals, suggest that the causal variants are beyond detection in the present study, due to more 
modest effect size (e.g. OR<1.47 for MAF≥10%) and/or imperfect capture by common variant-focused GWAS 
analyses.  
 
Re-evaluation of previous DKD associations  
The enlarged sample size provided an opportunity to investigate the previous, often contradictory reports of 
SNP associations.
28
 We selected signals from three sources: a literature-based meta-analysis of candidate gene 
associations;
28




; and GWASs on CKD irrespective of 
underlying pathology
20
. Many of these previous studies included subjects overlapping with those in the present 
analysis.  
We estimate >80% statistical power to detect associations with allelic OR≥1.25 and MAF≥10% at nominal 
significance (α=0.05; Supplemental Table 8) for the ‘late DKD’ phenotype, which was most commonly used in 
previous publications. We observed only a modest deviation from the null p-value distribution for the set of 
previously-associated variants, suggesting that many of these have been false positive findings (Supplemental 
Figure 4). Nevertheless, in addition to the AFF3 SNP associations described above, the associations between 
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rs2838302 (in SIK1) and ‘ESRD vs. non-ESRD’, and between rs17709344 (RGMA–MCTP2) and ‘CKD+DKD’ were 
directionally consistent and significant (p<1.1×10
-3
 to correct for 46 loci). The association between rs2838302 
(SIK1) and ‘ESRD vs. no DKD’ remained nominally significant (p=0.04) even after exclusion of the substantial 
overlap of the subjects (Supplemental Table 9). 
We observed directionally consistent associations (less stringent p<0.05) for variants near WNT4-ZBTB40, 
SEMA6D-SLC24A5, ELMO1, ERBB4, 4p15.1 and 13q regions (Supplemental Figure 5). However, at four of these 
loci, the modest evidence of association was lost when overlapping samples were removed. Independent 
replication of previously reported signals (directionally consistent p<0.05) was therefore restricted to the 
signals at ELMO1, 13q and SIK1 (Supplemental Table 9).  
 
DKD shows shared genetic background with obesity, T2D, and smoking cessation 
BMI, systolic blood pressure, serum lipids, and smoking have been associated with DKD in epidemiological 
studies
24,34-36
 while T2D, obesity, hypertension, and lipid disorders have been reported to cluster in families 
with DKD
11,12,37
, suggesting a shared genetic background or a close correlation amongst these phenotypes. We 









 intermediate phenotypes based on 10 to 96 established SNPs (p<5×10
-8
) for each phenotype from 
previously published GWAS. The GRS for increasing BMI
46
 was associated (p<2.6×10
-3
 to correct for 19 traits) 
with multiple DKD traits (p=2.2×10
-5
 for ‘late DKD‘; Figure 3; Supplemental Table 10), implicating a causal role 
of BMI for DKD. While observational studies have shown contradictory results,
51,52
 these findings are consistent 
with those from a recent Mendelian Randomization study including FinnDiane subjects.
53
 The GRS predisposing 
to T2D was associated with increased risk of multiple DKD traits (e.g. p=1.9×10
-3
 for ‘combined DKD’ excluding 
pleiotropic lipid and glycemic SNPs; p=6.1×10
-4
 for ‘combined DKD’ including pleiotropic lipid SNPs) in line with 
previous reports of parental T2D being associated with DKD in subjects with T1D.
12
 These data support a causal, 
mechanistic link between metabolic syndrome and DKD in T1D.
23
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We also applied the LD score regression method to estimate the genetic correlation between traits. In contrast 
to the GRS approach which uses only the most associated variants, this method examines the allelic effects of 
all SNPs in the meta-analysis.
54,55
 As expected, the seven DKD phenotypes were highly correlated with each 
other, at least in part due to overlapping phenotypic definitions, with the exception of ‘early DKD’ 
(Supplemental Figure 6). Smoking cessation was inversely correlated with ‘CKD’ (p=1.1×10
-4
) and other DKD 
traits (Figure 4). This is in line with a previous epidemiological study showing higher risk of DKD for smokers, 




Gene set enrichment analyses suggest glucuronidation and other pathways affecting DKD  
We performed gene set enrichment analyses (GSEA) of the GWAS results to identify biological pathways and 
processes enriched among the most significant GWAS signals. The ascorbate and aldarate metabolism, and 
pentose and glucuronate interconversions pathways showed significant enrichment (p<1.6×10
-5
 to correct for 
multiple tested pathways). Literature linking ascorbate metabolism to DKD is sparse, but cell studies have 
suggested a reduced uptake rate of ascorbic acid (vitamin C) in DKD,
56
 and vitamin C plus E supplementation 
was reported to improve glomerular function in T2D.
57
 In the latter pathway, the flagged genes overlapped 
especially the glucuronate sub-pathway (Supplemental Figure 7). Negatively charged glucuronic acid units on 
heparan sulfate side chains participate in the maintenance of the negative charge selectivity of the glomerular 
basement membrane in the kidneys, and their cleavage by heparanase (endo-ß-D-glucuronidase) has been 
suggested as an underlying cause for DKD.
58
 While knock-out of the HSPE (heparanase) gene protects mice 
from DKD,
59
 no specific genetic variants in or near HSPE have been associated with DKD. Other gene sets with 
less marked enrichment (false discovery rate (FDR)<0.05; Supplemental Table 11) included the cholesterol 
biosynthesis pathway (p=8.0×10
-4
) flagging among others the HMGCR gene (lowest p=0.023 for rs11726245 for 
‘CKD’), which encodes the main target of statins, commonly used for prevention of diabetic macrovascular 
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complications. Cholesterol levels are reported to be related to eGFR decline in T1D, while statin use improved 
eGFR in subjects with T2D in some
60




Single-marker association tests of whole exome sequencing show suggestive associations for ESRD 
To identify low frequency (1% ≤ MAF <5%) and rare (MAF<1%) coding variants contributing to DKD, we 
performed WES of 997 subjects with T1D from the FinnDiane, SDR and Steno Diabetes Center. To maximize 
power, subjects were ascertained from the tails of the liability distribution: we selected cases with onset of 
macroalbuminuria or ESRD relatively soon after diagnosis of T1D, and controls with normal AER despite 
prolonged duration of T1D (Supplemental Table 12). This setting allowed us to study the ‘late DKD’ and ‘ESRD 
vs. no DKD’ case–control contrasts (Figure 1).  
No associations were observed at exome-wide significance (p<5×10
-7
; Supplemental Figure 8). Variants in five 
loci reached a p-value of <1×10
-5 
for association with ‘ESRD vs. no DKD’ (Supplemental Tables 13 and 14) with 
the strongest associations obtained for an intronic SNP rs188427269 within NVL (MAF 0.2%, p=3.3×10
-7
) and 
for rs13003941 in the 3’UTR of ERBB4 (MAF 35%, p=3.5×10
-6
). Other variants in ERBB4 (not in LD with 
rs13003941) were previously suggestively associated with DKD,
15
 and ErbB4 was shown important for the 




Gene aggregate tests of WES  
To improve power to detect low frequency and rare variant associations, we performed gene-level aggregate 
tests using three complementary approaches: a variable threshold (VT) burden test,
63
 a dispersion test 
(SKAT),
64
 and a hybrid test (SKAT-O)
65
. No gene achieved exome-wide significance (p<2.5×10
-6
, adjusted for 
20,000 genes; Supplemental Figures 9 and 10). For the ‘late DKD’ phenotype, the lowest p-value was for GGA1 
(p=3.1×10
-5
; Supplemental Figure 11), showing rare (MAF≤0.13%)
66
 missense alleles in seven cases but no 
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controls across five variant sites (Supplemental Tables 15-17). For the ‘ESRD vs. no DKD’ phenotype, the 








Supplemental Figure 12, Supplemental Tables 18-20).  
While it has been hypothesized that common disease diagnoses are partially comprised of rare monogenic 
forms of the disease, we did not see enrichment in genes causing rare human glomerular diseases in our WES 
results (Supplemental Table 21). In addition, there was no enrichment between the WES signals and those 
arising from our GWAS studies. Thus, the variants and genes generating suggestive evidence for association in 
WES seem independent of rare variants identified for monogenic forms of kidney disease, and of the common 
variant contribution to DKD in subjects with T1D.  
 
Bivariate analysis of GWAS and WES data 
As some genetic factors may affect disease outcome only in the presence of interacting genetic factors, we 
complemented the GWAS and WES analyses using a multivariate variant selection method (ABACUS)
67
 applied 
to both GWAS and WES data. Although no variant reached simulation p-value (pS<5×10
-8
), suggestive evidence 
of association was obtained for variants in OSGIN1 in two different data sets (pS<5×10
-6
 for ‘ESRD vs. no DKD’ in 
EURODIAB GWAS and in Steno WES; Supplemental Tables 22 and 23). Functional clustering of the results 
pointed at processes previously linked with DKD such as cholesterol and sucrose/glucose metabolism and 
inflammatory response pathway (Supplemental Tables 24 and 25).  
 
Discussion 
This study represents a systematic evaluation of common genetic risk factors and rare coding variants for a 
broad range of kidney complication phenotypes in T1D. To complement the association analyses, we 
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performed various enrichment and correlation analyses considering the genome-wide content to obtain insight 
of the genetic architecture, biological background, and correlation with other traits.  
This study confirmed that renal complications in T1D are highly heritable, as a substantial proportion of the 
phenotypic variation can be captured by common variants on the GWAS chip, with the strongest heritability 
estimates observed for the most extreme phenotypic comparisons. This captured heritability could consist of 
common variants with modest effects, and/or variants of lower frequency, some of them imperfectly tagged by 
common SNPs. The limited evidence for linkage to DKD
68
 and general experience regarding the architecture of 
other common complex traits, suggest that it is unlikely that DKD risk is dominated by rare variants of large 
effect, though ultimately sequence based studies will be required for definitive evaluation. 
We found suggestive common variant signals for DKD in or near AFF3, CNTNAP2, NRG3, and PTPN13 genes, but 
additional data sets will be needed to confirm (or refute) these signals and to increase power to detect others. 
For example, the effective sample size required to implicate a risk allele of MAF 20% and allelic OR 1.2 at 
genome wide significance is ~15.000. We demonstrated that many previously claimed DKD associations signals 
are likely to be false positives, although modest, independent evidence was found for associations near 
ELMO1, 13q and SIK1 (p<0.05). While the three-stage analysis of this study brings together the largest studies 
with the largest number of participants with T1D for GWAS on DKD, the total sample size remains modest. 
Future efforts to identify novel genetic risk factors for DKD will require investment in additional sample 
ascertainment and genotyping.  
Different genetic factors may affect the various stages of DKD progression. To address the phenotypic 
heterogeneity within DKD, we applied selection of sub-phenotypes for the evaluation of renal complications. As 
various phenotypic comparisons yielded significant findings for different tests, these comparisons may address 
diverse aspects of the disease progression. Future studies would likely benefit from improved phenotyping and, 
in particular from the detailed longitudinal follow-up of research participants.  
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Even though this study concentrated on patients with T1D, some of the results may be extended to DKD in T2D 
as well. However, as the pathology behind renal complications in T2D is more heterogenous,
5
 with ageing, 
atherosclerosis and hypertension contributing appreciably to the renal function, the genetic background of 
DKD in T2D may have more features of the kidney disease in the general population.  
Although no novel susceptibility loci were identified in this study, some signals are starting to appear when we 
aggregated genetic data as in pathway analysis, genetic risk score and LD score regression analysis. The 
pathway analyses, for example, highlighted involvement of glucuronate interconversions pathway and 
supported the role of cholesterol metabolism in DKD. Analysis of genetic risk scores suggested that high BMI, 
as well as the genetic risk factors behind T2D, causally increase the risk of DKD in T1D. Finally, the LD score 
regression identified genetic correlation between smoking cessation and reduced risk of DKD in subjects with 
T1D, supporting the previous research of smoking as a risk factor for DKD
36
. Altogether, these results may 
provide valuable clues to the biological processes relevant to the pathogenesis of DKD. 
  
Concise Methods 
Subjects with T1D in GWAS and WES 
The GWAS discovery stage included subjects with T1D from the FinnDiane Study,
23







. WES included subjects from FinnDiane, SDR, and Steno Diabetes Center 
(characterized in Supplemental Table 12). All studies were approved by the local ethics committees and 
conducted according to the principles of the Declaration of Helsinki. Written consent was obtained from the 
participants in FinnDiane, EURODIAB, SDR and Steno Studies. In the NFS-ORPS study, written consent was 
obtained from parents, and verbal assent was obtained from children.  
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Phenotype definitions: All subjects had T1D as diagnosed by their attending physician, with age at diabetes 
onset ≤40 years and insulin treatment initiated within one year of diagnosis. The kidney status was classified 
based on AER and eGFR (please see Complete Methods and Supplemental Table 26). Patients receiving dialysis 
treatment, with a kidney transplant, or with an eGFR ≤15 ml/min/1.73m
2
 were defined to have ESRD. Based on 
these definitions, we analysed seven different case – control phenotypes (Figure 1).  
Patient selection for WES: Patients were selected from the extreme ends of the liability distribution of DKD 
from each participating study. Cases had rapid onset of macroalbuminuria (within 20/25 years of diabetes 
onset in FinnDiane and Steno, respectively; no threshold in SDR) or ESRD (onset within 25 years of diabetes 
onset in FinnDiane and Steno). Controls were subjects with normal AER despite prolonged duration of T1D (≥ 
32, 30, or 27 years in FinnDiane, Steno, and SDR, respectively). In addition, the FinnDiane controls were 
enriched for higher HbA1C values (excluding subjects with HbA1C < 6.5 %).  
 
Genotypes 
Genome-wide genotyping and imputation of the discovery cohorts: The genome-wide genotyping of 
the subjects in the SDR, NFS-ORPS, and EURODIAB was performed with the Illumina OmniExpress assays 
(Illumina, San Diego, CA, USA). In quality control, samples with a call rate <98%, gender discrepancy, extremely 
high or low heterozygosity, or excess of estimated relatedness, were removed. Common SNPs (MAF≥5%) with 
genotyping rate <95% or not in Hardy-Weinberg equilibrium (HWE; p ≤5.7×10
-7
) were removed. For low-
frequency SNPs (MAF 1% – 5%), the thresholds were 99% and p<10
-4
, respectively. In the FinnDiane Study, 
genotyping was performed with the Illumina 610Quad assay and the quality control was similar to the other 
studies, as described previously in detail.
15
 Principal component analysis was performed in all cohorts with 
Eigensoft.
69
 Imputation was performed with IMPUTE2
70
 using the 1000 Genomes project (phase 1 v.3, released 
March 2012) as the imputation reference panel.
71
 Variants were filtered post-imputation to those with MAF ≥ 
1%, minor allele count ≥10 in both cases and controls, and SNPtest INFO estimate of imputation quality ≥0.4.  
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Whole exome sequencing and variant calling: Samples were sequenced at two centres. Sequencing was 
performed on an Illumina HiSeq2000. We required an average 20x target capture above 80% coverage, 
otherwise additional DNA was requested to ‘top up’ the sample. This resulted in mean sequencing depth of 
54.97 (FinnDiane) and 42.23 (SDR and Steno) bases per position. After additional sequencing 497 samples were 
included from FinnDiane and 500 from SDR and Steno. Samples were mapped with Burrows-Wheeler aligner 
v7.4. Genome analysis toolkit v2.1 (GATK) was used to refine and recalibrate the sequences and to call variants. 
Polymorphic variants (MAF>0) with a mapping quality < 250, HWE p-value >1×10
-10
 and call rate ≥75% were 
retained in the analysis. Samples with ≥10% missingness or extreme heterozygosity were excluded. Population 





 for functional class and transcript.  
With 530,565 variants (491,553 SNPs and 39,012 indels) across 479 controls and 481 cases after the quality 
control, each individual carried a mean of 7,566 synonymous, 6,452 missense and 103 protein truncating 
variants. The lower number of total variant sites compared to other, more outbred populations
74
 is in line with 




Statistical methods  
Heritability estimates: The narrow-sense heritability of the kidney phenotypes was estimated as the 
proportion of the phenotypic variance explained by the additive effects of the genotyped SNPs based on the 
FinnDiane GWAS data using the GCTA v. 0.93.9, excluding samples with estimated relatedness ≥ 0.025.
76
 The 
observed variance explained was transformed to the underlying population scale based on rough prevalence 
estimates as given in Supplemental Table 1. The heritability was estimated without covariates, and adjusting 
for sex, duration of T1D and age at T1D onset.  
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GWAS analysis: The genome-wide association analyses in stage 1 studies were performed with two methods 
in parallel. To obtain stable effect size estimates, we performed additive test for association using SNPtest with 
the score method adjusted for sex, diabetes duration, age at diabetes onset, and the two first principal 
components. P-values were obtained with a variance component based mixed model method, EMMAX, which 
accounts for the sample structure, allowing to include relatives in the analysis.
77
 Models were adjusted for sex, 
diabetes duration and age at diabetes onset and the kinship matrix was calculated with EMMAX. EMMAX 
algorithm was implemented with the EPACTS software (www.sph.umich.edu/csg/kang/epacts/). Meta-analyses 





while p-values were combined based on the study-wise p-values, sample sizes and effect directions (METAL
79
). 
Meta-analysis results were further filtered to those with valid results from at least two studies. P-values below 
5×10
-8
 were considered genome-wide significant, not correcting for multiple testing due to seven phenotypic 
comparisons, as the case and control groups were overlapping and the traits were correlated with each other.  
Power calculations were performed with the genetic power calculator (pngu.mgh.harvard.edu/~purcell/gpc/) 
for simple case-control setting,
80




Replication: Independent variants with p<5×10-6 were selected for in silico replication in six additional studies: 
the All Ireland – Warren 3 – Genetics of Kidneys in Diabetes UK collection (UK-ROI)
15
 and the Genetics of 
Kidneys in Diabetes US Study (GoKinD US)
15
 from the GENIE Consortium, the Diabetes Control and 
Complications Trial and the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study
82,83
, 
1,073 subjects from the Joslin Diabetes Center T1D nephropathy collection, and the French, Belgian and Danish 
subjects (the Steno Diabetes Center) from the French-Danish Effort
84
 (Supplemental Tables 2 and 3). After in 
silico replication, variants that replicated with a p<0.05 or had a combined p-value < 1×10
-7
 after meta-analysis 
were selected for de novo genotyping with TaqMan in 1,095 additional FinnDiane patients, not part of the 
GWAS (Supplemental Table 2). rs1989248 was not successfully genotyped. Association testing was performed 
Page 30 of 145
ScholarOne support: 888-503-1050






























































Genome-wide dissection of diabetic kidney disease 
 - 18 - 
with logistic regression (implemented in PLINK or SNPtest, depending on the study), adjusted for sex, duration 
of diabetes, age at diabetes onset, and study specific covariates.  







), systolic blood pressure (SBP),
49
 low-density lipoprotein 






 (including all 
SNPs, and without any other effects other than on T2D or lipids
50
 and T2D or glycemic traits
41,85
), 2-hr glucose 
(adjusted for BMI),
40
 fasting glucose (adjusted for BMI),
41
 glycated haemoglobin (HbA1c),
42
 fasting insulin 
(natural log transformed and adjusted for BMI),
41





 and insulin resistance
45
 were included in a genetic risk score (GRS) for each trait 
respectively. The GRS was weighted by the allelic effect of each variant on the DKD risk factor and associated 
with the DKD phenotypes using the stage 1 GWAS meta-analysis data.
49
 The lipid GRS were restricted to 
variants that predicted that specific trait and removed those that had effects on other lipid traits. We did not 
include a GRS for smoking behaviours as there were too few genome-wide significant associations to form a 
sufficient instrument.   
LD score regression to estimate genetic correlation: To estimate the genetic correlation between the 
GWAS stage 1 meta-analysis results for DKD phenotypes, and the related traits, we assembled the genome-
wide summary statistics from all the studies used to calculate GRS except for systolic blood pressure and T1D 
as the full summary statistics were not available. We additionally computed genetic correlation with smoking 
behaviour phenotypes (cigarettes per day, smoking addiction, smoking cessation and age at smoking onset).
86
  
Gene set enrichment analyses: gene set enrichment analysis was performed in the GWAS stage 1 meta-
analysis results with the MAGENTA(vs.2)
87
 applied on 10,992 partially overlapping gene sets from GO, 
PANTHER, INGENUITY, KEGG, REACTOME, and BIOCARTA data bases; 3,126 gene sets with ≥10 genes were 
analysed. The 95 percentile cut-off for the gene scores was employed to define the significant results.  
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Correction for multiple testing: The significance threshold for the results of the evaluation of previous loci, 
GRS, LD score regression, and pathway enrichment analyses were Bonferroni corrected for multiple testing 
with α=0.05 significance level, accounting for the number of tested loci, traits, or pathways. The results were 
not corrected for the seven phenotypic comparisons due to a considerable overlap of the case and control 
groups. 
WES single variant analysis: Single variants were tested for association with DKD (cases N=481, controls 
N=479) and ESRD (cases N=168, controls N=479) using the logistic score test
88
 implemented in Epacts, with sex 
and two principal components as covariates. Related individuals, monomorphic SNPs and those with standard 
error greater than 10 were excluded from the analysis. While the study setting provided low statistical power 
to detect rare variants (MAF<1%) with exome-wide significance (p<9×10
-8
 to correct for 530,776 tested 
variants) in line with previous reports on the statistical power to detect rare variants,
89
 we had sufficient power 
(80%) to detect a low frequency variant (MAF=5%) with a large OR of 5.65 (Supplemental Figure 13).  
WES gene-based analysis: We applied three series of gene based tests: a burden test (VT) 63 that assumes 
the direction of effect of grouped variants is the same, a dispersion test (SKAT) 
64
 that performs well when the 
direction of variant effect differs, and a hybrid (SKAT-O) 
65
 that uses multiple methods in a single test. Analyses 
were adjusted for sex and principal components. For all three tests we grouped variants into four categories: 
protein truncating variants (PTV; e.g. nonsense, frameshift, essential splice site), deleterious protein altering 
variants sub-divided into “strict” and “broad” grouping if predicted deleterious by all five/ at least one 
annotation algorithm, and any protein altering variants (e.g. missense, in-frame indel, non-essential splice-site. 
These four groups are referred to as 1) PTV-only, 2) PTV+strict, 3 ) PTV+broad, and 4) PTV+missense, from the 
strictest to the most permissive class. A MAF threshold of 1% was applied to the more permissive masks 
PTV+missense and PTV+broad to exclude common variants from the WES analysis.  
WES gene set enrichment analysis: A total of 43 gene sets were created, based on top findings from the 
GWAS analyses, kidney-related functional terms in public databases, text mining approaches and kidney gene 
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expression (Supplemental Table 21). These gene sets were analysed for enrichment in ‘Late DKD’ WES 
association results (SKAT-O, all four masks) using the GSEA method with SKAT-O’s p-value as the ranking 
statistic
90
. To guard against potential miscalibration of GSEA’s reported p-values we conducted 100 
permutations of case/control status and subsequently re-ran burden tests and GSEA analysis for each 
permutation. Significance of enrichment was validated with permutation. For validation of enrichment of 
GWAS result, the samples in WES were removed from the GWAS data and the analyses were repeated. 
Bivariate analysis of GWAS and WES data: We applied ABACUS67 to the individual GWAS discovery cohorts 
on each of the seven different case-control phenotypes. In addition, ABACUS was applied to the WES cohorts 
(FinnDiane, Steno and SDR) on the two phenotypic comparisons. SNP-sets were defined based on REACTOME, 
KEGG and GO Biological Processes. To analyse non-annotated and intergenic SNPs, we also defined SNP-sets of 
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Figure legends 1 
Figure 1: Schematic picture of the DKD phenotypic comparisons based on measured AER and eGFR, 2 
encompassing different stages and severity of DKD. ‘Combined DKD’ and ‘Late DKD’ (conventionally used in 3 
many previous genetic studies of DKD) are expected to capture genetic factors affecting DKD in general; ‘Early 4 
DKD’ comparison targets the  genetic factors affecting the initiation of DKD, or with milder effect on the 5 
phenotype, whereas the two ESRD-based case definitions are expected to capture factors related to the late 6 
progression of DKD such as fibrotic processes, or genetic factors with particularly strong effect on the 7 
phenotype. While the ‘CKD’ phenotype may reveal  genetic factors for reduced renal function irrespective of 8 
the presence of albuminuria, the ‘CKD+DKD’ phenotype is an extreme phenotype that requires that controls 9 
have no signs of renal complications (neither AER or eGFR based). AER thresholds are given in µg/min, eGFR 10 
thresholds in ml/min per 1.73 m
2
. Normo: Normal AER; miA: microalbuminuria; maA: macroalbuminuria. 11 
Number of samples per sub-phenotype: Normo: 2,593; miA: 800; maA: 944; ESRD: 813; no CKD: 2,909; CKD: 12 
1,255; no CKD, no DKD: 2,018; CKD+DKD: 1,117. 13 
 14 
Figure 2: The proportion of phenotypic variance explained by genotypes (V(G)/V(p_L)), i.e. the narrow-sense 15 
heritability, of the seven studied DKD phenotypic comparisons indicate high heritability especially for the 16 
more extreme phenotype definitions. Error bars represent the standard error.  17 
 18 
Figure 3: The genetic risk scores (GRS) for body mass index (BMI) and type 2 diabetes (T2D) were associated 19 
with diabetic kidney disease (DKD) phenotypes in subjects with type 1 diabetes. A GRS for body mass index 20 
(BMI; z-transformed) was associated (p<2.6×10
-3
 to account for multiple testing, 19 GRS traits) with combined 21 
and late DKD, and CKD phenotypes; GRS for T2D was associated with late DKD.  22 
 23 
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Figure 4: Genome-wide comparison of DKD traits and other phenotypes, evaluated with LD score regression, 24 
shows negative correlation between DKD traits, and smoking cessation. Significant correlations (p<0.0029 to 25 
account for multiple testing, 17 related phenotypes) are indicated with *. Bars represent 95% confidence 26 
intervals.  27 
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TABLES 28 
Table 1: Clinical characteristics of the subjects, divided into cases and controls based on the ‘combined DKD’ phenotype definition 29 
 FinnDiane (N=3,415) EURODIAB (N=789) SDR (N=558) Cambridge (N=396) 
Cohort (N) Cases Controls Cases Controls Cases Controls Cases Controls 
N 1,802 1,613 298 491 266 292 197 199 
N Males (%) 1,067 (59) 669 (41) 170 (57.2) 222 (45.3) 150 (56) 160 (55) 109 (54) 93 (47) 
Age of onset of diabetes [year]
a
 13.4 (8.4) 15.6 (8.8) 16.7 (8.3) 17.9 (8.1) 15.9 (9.4) 17.1 (9.5) 9.1 (4.0) 7.6 (6.0) 
Age [year]
a
 45.1 (11.1) 43.6 (11.7) 40.3 (10.3) 42.9 (10.2) 48.2 (14.5) 48.7 (13.2) 17.0 (5.7) 23.4 (10.2) 
Duration of diabetes [year]
a





 25.7 (4.1) 25.3 (3.5) 24.6 (3.7) 25.1 (3.42) 24.6 (3.3) 24.4 (3.2) - - 
HbA1C [%]
a
 8.7 (1.6) 8.1 (1.2) 8.3 (1.9) 7.7 (1.6) 7.9 (1.1) 7.1 (0.9) 10.5 (2.3) 8.7 (1.6) 
HbA1C [mmol/mol]
a
 72 (17) 65 (13) 68 (21) 61 (18) 63 (12) 54 (10) 91 (25) 72 (18) 
a
mean (sd) 30 
 31 
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Table 2: Association analysis results for the top SNPs from the GWAS discovery + in silico replication analysis, selected for additional de novo 32 
replication. 33 
  SNP rs61277444* rs7562121 rs1989248 rs72809865 
  CHR 4 2 7 10 
  Gene** in PTPN13 in AFF3 23kb to CNTNAP2 350kb to NRG3 
  Pheno 
a,b 
ESRD vs. non-ESRD 
b 
ESRD vs. no DKD 
a,b 









Stage I N 813/3,995 813/2,394 813/3,995 1,117/2,018 813/2,394 2,563/2,593 
EAF 0.09 0.09 0.23 0.28 0.28 0.16 
OR  1.55   1.58   1.46   1.28   1.40   1.30  





















 0.021 0.047 
Stage III N 94/993 94/627 67/822     367/516 
P 0.19 0.14 0.59     0.54 
All N 1,871/9,794 1,871/6,208 1,844/9,623 2,221/3,999 1,777/5,581 5,589/6,951 
N total 11,665 8,079 11,467 6,220 7,358 12,540 
OR 1.41 1.42 1.27 1.26 1.29 1.17 


















 for discovery + stage two meta-34 
analysis. 
b 
p-value < 0.05 in the in silico replication for the phenotype selected for replication; *Due to moderate imputation quality at the discovery 35 
stage, rs61277444 was directly genotyped in 2,913/3,415 FinnDiane subjects. The association in FinnDiane was moderately attenuated from OR=1.49 36 
(95% CI 1.19 - 1.86, p=4.5×10
-4
; ESRD vs. non-ESRD) and OR=1.50 (95% CI 1.18 - 1.91, p=1×10
-3
; ESRD vs. no DKD) with the imputed data to OR=1.36 37 
(95% CI 1.11 - 1.66, p=3.0×10
-3
; ESRD vs. non-ESRD) and OR=1.40 (95% CI 1.11 - 1.75, p=3.9×10
-3
; ESRD vs. no DKD) using directly genotyped data. ** 38 
The closest gene/genes. 39 
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COMPLETE METHODS 
Subjects with Type 1 diabetes (T1D)  
Subjects in the GWAS discovery studies: The GWAS discovery stage included subjects with T1D from four studies: 
The Finnish Diabetic Nephropathy (FinnDiane) Study1,2, the EURODIAB Family Study3, the Scania Diabetes Registry 
(SDR)4, and the UK Nephropathy Family Study and Oxford Regional Prospective Study (NFS-ORPS/ Cambridge)5,6. All 
studies were approved by the local ethics committees and conducted according to the principles of the Declaration of 
Helsinki. Written consent was obtained from the participants in FinnDiane, Eurodiab, SDR and Steno Studies. In the 
NFS-ORPS study, written consent was obtained from parents, and verbal assent was obtained from children.  
The Finnish Diabetic Nephropathy (FinnDiane) Study1,2: FinnDiane is a Finnish nationwide prospective 
multicenter study, with the aim to identify genetic, clinical, biochemical and environmental risk factors for diabetic 
complications. The study includes patients from all five Finnish University Central Hospitals, all 16 central hospitals, 
and 56 regional hospitals and health care centers. The study protocol and patient recruitment criteria have been 
previously described 1. In short, patients with type 1 diabetes (T1D) were recruited at their own health care center by 
their attending physician, who completes the main questionnaire. Blood and urine samples are sent to the central 
laboratory of the FinnDiane Study. The patients have been followed up in  prospective follow-up visits roughly 5-7 
years after the baseline visit. In addition, FinnDiane Study includes pati nts with type 1 diabetes recruited by the 
Finnish National Institute of Health and Welfare across Finland. Retrospective data has been retrieved from medical 
records. Furthermore, information on major clinical events, such as the onset of ESRD, can be retrieved from the 
Finnish Hospital Discharge Registry (HILMO). 
The EURODIAB Family Study3: The Eurodiab Insulin Dependent Diabetes (IDDM) Complications Study was a cross-
sectional investigation of a stratified random sample of IDDM patients attending 31 clinics in 16 European countries 
that were carried out in 1989/91. These subjects were then followed up around 6-8 years later in the EURODIAB 
Prospective Complications Study. T1D was defined as diabetes onset <35 years with insulin within one year of 
diagnosis. This collection was supplemented by additional T1D cases with nephropathy at those EURODIAB 
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participating centres even if the patient hadn’t participated in the original EURODIAB IDDM Complications study. We 
also recruited several additional centres (UK, Austria & Poland) to focus specifically on late stage and dialysis patients. 
The current GWAS study comprised cases with micro- or macroalbuminuria, ESRD, or elevated serum creatinine (>200 
µmol/lit) consistent with ESRD. Cases were captured from several sources (EURODIAB at baseline, EURODIAB at 
follow up, additional cases from these centres not in the original cohort study and renal failure cases from several 
new non-EURODIAB centres). Non-DKD controls were only recruited from the original Eurodiab IDDM Complications 
Study cohort. They had at least 15 years of T1D duration and remained normoalbuminuric for the follow-up period. In 
addition to local MICRAL strip testing, the controls had normoalbuminuria confirmed by the central EURODIAB on 
two overnight collections at follow up and on one collection at baseline.   
Scania Diabetes Registry (SDR)4: Patients in SDR were randomly collected from the Department of Endocrinology, 
Malmö Sweden and surrounding clinics in Skåne (Scania) Sweden. Patients of known non-Scandinavian origin were 
excluded from the analysis. Diabetes classification was done based on presence of GAD antibodies and low c-peptide 
levels, or in case of incomplete information, based on the diagnosis given by the treating physician. All patients with 
T1D were diagnosed before 35 years of age. 
The UK Nephropathy Family Study and Oxford Regional Prospective Study (NFS-ORPS/ Cambridge)5,6:  
ORPS is a population-based inception cohort of childhood-onset T1D, established between 1986 and 1997, with the 
aim of assessing the natural history of microalbuminuria 5. Children diagnosed with T1D under the age of 16 years, in 
the defined geographic region of the Oxford Health Authority, were recruited within 3 months of diagnosis of Type 1 
diabetes to receive annual assessments. Ninety-one percent of eligible children were recruited at a mean age of 8.8 
years and were followed annually thereafter. The overall dropout rate for the ORPS cohort has been 9.6%.  
The NFS is a prospective study started in the year 2000 with the aim of assessing factors influencing changes in 
albumin excretion during adolescence in young people with T1D 6. Between 2000 and 2005, adolescents (aged 10–18 
years), diagnosed with T1D before the age of 16 years, were recruited throughout England. Cases of secondary 
diabetes treated with insulin or maturity-onset diabetes of the young were identified by clinical histories and 
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examination of case records, and were excluded. Similarly, children with chronic renal disease or other chronic 
diseases likely to affect renal function were excluded. 
Both cohorts were monitored with annual centralized assessments of ACR, based on three consecutive early morning 
urine samples. 
The studies received ethical approval from district ethics committees. Written consent was obtained from parents, 
and verbal assent was obtained from children. 
 
Phenotype definitions: All subjects had T1D as diagnosed by their attending physician. In addition, subjects were 
limited to those with the age at diabetes onset ≤40 years and insulin treatment initiated within one year of diagnosis. 
The kidney status was classified based on the urinary albumin excretion rate (AER) and on the estimated glomerular 
filtration rate (eGFR). The subjects were classified as normal AER, microalbuminuria or macroalbuminuria based on 
two out of three consecutive urine samples surpassing the required threshold (Supplemental Table 26). Patients 
receiving dialysis treatment, with a kidney transplant, or with an eGFR ≤15 ml/min/1.73m2 were defined to have 
ESRD. eGFR was calculated either with the MDRD4 7 or the CKD-EPI 8 formula depending on the study. In addition, 
subjects were classified to CKD classes: No CKD was defined as eGFR ≥60ml/min/1.73m2 (i.e. CKD classes 1 and 2), 
and CKD as eGFR <60 ml/min/1.73m2 (i.e. CKD classes 3-5). Based on these definitions, we analysed seven different 
case – control phenotypes: i) cases with DKD (microalbuminuria or worse) versus controls with normal AER; ii) cases 
with macroalbuminuria or ESRD versus normal AER; iii) cases with ESRD versus controls with normal AER; iv) cases 
with ESRD versus everyone else; v) cases with microalbuminuria versus controls with normal AER; vi) cases with CKD 
versus controls without CKD; vii) cases with severe CKD (eGFR ≤45 ml/min/1.73m2) and microalbuminuria or worse 
versus controls with normal AER and no CKD. The number of subjects in the four discovery studies is specified for the 
different phenotype definitions in  Supplemental Table 3.  
Patient selection for WES: WES included subjects from FinnDiane, SDR, and Steno Diabetes Center (Supplemental 
Table 12). Whilst we adopted broadly similar schemes for ascertaining the extremes in each of three contributing 
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studies, there were some differences. Patients were selected from the extreme ends of the liability distribution of 
DKD from each participating study (FinnDiane, SDR, and Steno). Cases were defined as subjects with rapid onset of 
macroalbuminuria (within 20/25 years of diabetes onset in FinnDiane and Steno, respectively; no threshold in SDR) or 
ESRD (onset within 25 years of diabetes onset in FinnDiane and Steno). Controls were subjects with normal AER 
despite prolonged duration of T1D (≥ 32, 30, or 27 years in FinnDiane, Steno, and SDR, respectively). In addition, the 
FinnDiane controls were enriched for higher HbA1C values (excluding subjects with HbA1C < 6.5 %), and a half of the 
controls were selected to have proliferative diabetic retinopathy or retinal laser treatment.  
 
Genotypes 
Genome-wide genotyping and imputation of the discovery cohorts: The genome-wide genotyping of the 
subjects in the SDR, NFS-ORPS, and EURODIAB (a sub-study of the EURODIAB PCS) was performed within the SUMMIT 
project with the Illumina OmniExpress assays (Illumina, San Diego, CA, USA). Samples with a call rate <98% or gender 
discrepancy were removed in the first step of quality control. Subsequently, common single nucleotide 
polymorphisms (SNPs; i.e. minor allele frequency (MAF) ≥0.05) with low genotyping rate (<95%) or not in Hardy-
Weinberg equilibrium (HWE; p-value≤5.7×10-7) were removed. For non-common SNPs (MAF 0.01 – 0.05), the 
thresholds were 99% and p-value <10-4, respectively. Samples with extremely high or low heterozygosity or excess of 
estimated relatedness were removed due to suspected sample contamination or issues in the sample processing, 
based on study specific distributions. In the FinnDiane Study, genotyping was performed with the Illumina 610Quad 
assay and the quality control was similar to the other studies, as described previously in detail 2. Principal component 
analysis was performed in all cohorts with the Eigenstrat software (Eigensoft v. 3.0, 9).  
After the quality control, the SNP positions were converted to human genome build 37, and genome-wide imputation 
was performed with IMPUTE2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html 10) using 1,092 samples from 
the 1000 Genomes project (http://www.1000genomes.org, phase 1 v.3, released March 2012) as the imputation 
reference panel 11. The pre-phasing and imputation were performed with the default parameters and the effective 
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sample size of 20,000 as suggested in the IMPUTE2 tutorial. Variants were filtered post-imputation to those with MAF 
≥ 0.01, minor allele count ≥10 in both cases and controls, and SNPtest INFO estimate of imputation quality ≥0.4.  
Whole exome sequencing and variant calling: Samples were sequenced at two centres. The samples were 
prepared using the Illumina TruSeq™ DNA LT Sample Prep Kit, pooled into multiplexes of five and were captured 
using the Illumina TruSeq™ Exome Enrichment Kit. The concentration of each library was determined by real-time 
qPCR using Agilent qPCR Library Quantification Kit and a MX3005P instrument (Agilent). Sequencing was performed 
on an Illumina HiSeq2000, using 100bp paired end reads and with an anticipated minimum yield of 30 Gb per lane. 
Five exomes of 63Mb were run per lane (single lane for most), aiming for approximately 100x read depth. We 
required an average 20x target capture above 80% coverage, otherwise additional DNA was requested to ‘top up’ the 
sample. This resulted in mean sequencing depth of 54.97 (FinnDiane) and 42.23 (SDR and Steno) bases per position. 
After additional sequencing 497 samples were included from FinnDiane and 500 from SDR and Steno.  
Samples were mapped with Burrows-Wheeler aligner v7.4 (BWA), refined by removing duplicates and realigning 
around known insertions and deletions (INDELs), and recalibrated using genome analysis toolkit v2.1 (GATK). GATK’s 
UnifiedGenotyper was applied to call variants, followed by recalibration of SNVs using VQSR and hard filtering of 
INDELs. 
Polymorphic variants (MAF>0) with a mapping quality < 250, HWE p-value >1×10-10 and call rate ≥75% were retained 
in the analysis. Samples with ≥10% missingness or heterozygosity rate greater or less than 3 standard deviations from 
the sample mean were excluded. Population outliers (based on visual inspection of the four first principal 
components), duplicates and related samples were removed. Variants were annotated using CHAos 
(http://www.well.ox.ac.uk/~kgaulton/chaos.shtml), snpEff (http://snpeff.sourceforge.net/ 12) and VEP 
(http://www.ensembl.org/info/docs/tools/vep/ 13) for functional class and transcript.  
With 530,565 variants (491,553 SNPs and 39,012 indels) across 479 controls and 481 cases after the quality control, 
each individual carried a mean of 7,566 synonymous, 6,452 missense and 103 protein truncating variants. The lower 
number of total variant sites compared to other, more outbred populations 14 is in line with fewer variable sites seen 
in founder populations such as the Finns 15.  
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Statistical methods  
Heritability estimates: The narrow-sense heritability of the kidney phenotypes was estimated as the proportion of 
the phenotypic variance explained by the additive effects of the genotyped SNPs based on the FinnDiane GWAS data 
using the GCTA v. 0.93.9, excluding samples with estimated relatedness ≥ 0.025 16. The observed variance explained 
was transformed to the underlying population scale based on rough prevalence estimates as given in Supplemental 
Table 1. The heritability was estimated without covariates, and adjusting for sex, duration of T1D and age at T1D 
onset.  
GWAS analysis: The genome-wide association analysis was performed with two methods in parallel. To obtain 
stable effect size estimates, we performed additive test for association using SNPtest with the score method and 
adjusted for sex, diabetes duration and age at diabetes onset 17, and the two first principal components calculated 
with the Eigenstrat software (Eigensoft v. 3.0, 9). Close relatives were not included in the analysis. P-values were 
obtained with a variance component based mixed model method, EMMAX, which accounts for the sample structure, 
allowing to include close relatives in the analysis 18. Models were adjusted for sex, diabetes duration and age at 
diabetes onset and the kinship matrix was calculated with EMMAX. EMMAX algorithm was implemented with the 
EPACTS software (www.sph.umich.edu/csg/kang/epacts/). 
Meta-analyses of the effect sizes were performed with the fixed-effect inverse variance method implemented in 
GWAMA 19). P-values were combined with METAL software based on the study-wise p-values, sample sizes and effect 
directions 20. Meta-analysis results were further filtered to those with valid results from at least two studies. P-values 
below 5×10-8 were considered genome-wide significant, not correcting for multiple testing due to seven phenotypic 
comparisons, as the case and control groups were overlapping and the traits were correlated with each other.  
Power calculations were performed with the genetic power calculator (pngu.mgh.harvard.edu/~purcell/gpc/) for 
simple case-control setting,21 and with Power Calculator for Two Stage Association Studies (CaTS; 
http://csg.sph.umich.edu//abecasis/cats/).22 
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In silico Replication: Independent variants with a p-value < 5×10-6 were selected for in silico replication. Variants 
were defined independent if they were at least 100 kilo base pair (kbp) away from each other. The selection was 
performed separately for each phenotype, and therefore, multiple variants were selected for some loci with different 
lead variants for different phenotypes. Replication consisted of six additional studies: the All Ireland – Warren 3 – 
Genetics of Kidneys in Diabetes UK collection (UK-ROI) 2 and the Genetics of Kidneys in Diabetes US Study (GoKinD 
US) 2 from the GENIE Consortium, the Diabetes Control and Complications Trial and the Epidemiology of Diabetes 
Interventions and Complications (DCCT/EDIC) study 23,24, 1,073 subjects from the Joslin Diabetes Center T1D 
nephropathy collection, and the French, Belgian and Danish subjects (the Steno Diabetes Center) from the French-
Danish Effort 25. The number of subjects in each study is given in Supplemental Table 3. Association testing was 
performed with PLINK or SNPtest depending on the study, using the same covariates as in the discovery stage.  
De novo replication and genotyping: After in silico replication, variants replicated with a p<0.05 or a combined p-
value < 1×10-7 after meta-analysis were selected for de novo replication. A total of 1,095 additional FinnDiane 
patients, not part of the GWAS, were genotyped for stage 3 analysis with TaqMan (Supplemental Table 2). 
Additionally, subjects with T1D from the Diabetes in Region of Vaasa (DIREVA) study, a follow-up study from Finland 
with >5,000 subjects with diabetes, were genotyped together with DIREVA subjects with T2D using either Taqman 
(rs72809865) or Sequenom (the rest). rs1989248 was not successfully genotyped in either de novo replication study. 
Additionally, genotyping of rs72809865 was unsuccessful in DIREVA, and only four cases with T1D and ESRD were 
identified in DIREVA after removing subjects that were included in the FinnDiane discovery study. Thus, no SNPs 
remained for analysis from DIREVA. Association analysis was performed in the FinnDiane replication cohort similarly 
to in silico replication using logistic regression and adjusted for sex, duration of diabetes, and age at diabetes onset. 
As one of the lead SNPs, rs61277444 was imputed with only moderate quality, that SNP was de novo genotyped also 
in 2,913 FinnDiane subjects from the discovery study. Concordant to the imputation quality INFO score of 0.83 in 
FinnDiane, the de novo genotyping agreed with the imputed genotypes (converted to most likely genotypes with 
genotype likelihood threshold of 0.9) for 73% of the samples.   
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Genetic risk score analysis: SNPs associated with Waist-Hip-ratio (adjusted for BMI, NSNPs=54)
26, BMI 
(untransformed, NSNPs=96 
27 and z-transformed, NSNPs=24 
28), systolic blood pressure (SBP, NSNPs=22)
29, low-density 
lipoprotein cholesterol (LDL-C, NSNPs=24), triglycerides (TRIG, NSNPs=20), high-density lipoprotein cholesterol (HDL-C, 
NSNPs=26)
30, T1D (NSNPs=51) 
31, T2D 32 (including all SNPs (NSNPs=70), and without any other effects other than on T2D or 
lipids (NSNPs=56)
30 and T2D or glycemic traits (NSNPs=62)
33,34), 2-hr glucose (adjusted for BMI, NSNPs=15)
35, fasting 
glucose (FG, adjusted for BMI, NSNPs=21) 
34, glycated haemoglobin (HbA1c, NSNPs=15)
36, fasting insulin (natural log 
transformed and adjusted for BMI, NSNPs=13)
34, fasting pro-insulin (adjusted for BMI and FG, NSNPs=10)
37, HOMA-B 
(NSNPs=15), HOMA-IR (NSNPs=15)
38 and insulin resistance 39 at genome-wide significance were included in a genetic risk 
score (GRS) for each trait respectively. The GRS was weighted by the allelic effect of each variant on the DKD risk 
factor and associated with the DKD phenotypes using meta-analysis data 29. The lipid GRS were restricted to variants 
that predicted that specific trait and removed those that had effects on other lipid traits. We did not include a GRS for 
smoking behaviours as there were too few genome-wide significant associations to form a sufficient instrument.   
LD score regression to estimate genetic correlation: Genetic correlation was estimated between the GWAS 
stage 1 meta-analysis results of the seven binary DKD phenotypes, and related traits. We assembled the summary 
statistics from all the studies used to calculate genetic risk scor s except for systolic blood pressure and T1D as the 
full summary statistics were not available. We restricted the GRS and LD score regression analyses to reports from full 
genome-wide SNP data as LDScore regression takes the effect of all SNPs into account. We additionally computed 
genetic correlation with smoking behaviour phenotypes (cigarettes per day, smoking addiction, smoking cessation 
and age at smoking onset).40   
Gene set enrichment analyses: MAGENTA gene set enrichment analysis was performed in the GWAS stage 1 
meta-analysis results with the MAGENTA (vs.2) software, 41 applied on 10,992 partially overlapping gene sets from 
GO, PANTHER, INGENUITY, KEGG, REACTOME, and BIOCARTA data bases; 3,126 gene sets with ≥10 genes were 
analysed. Gene boundaries used for mapping SNPs onto genes were 110kb upstream to most extreme gene transcript 
start position, and 40kb downstream to most extreme gene transcript end position. The 95 percentile cut-off for the 
gene scores was employed to define the significant results.  
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Correction for multiple testing: The significance threshold for the results of the evaluation of previous loci, GRS, LD 
score regression, and pathway enrichment analyses were Bonferroni corrected for multiple testing with α=0.05 
significance level, accounting for the number of performed tests. The results were not corrected for the seven 
phenotypic comparisons due to a considerable overlap of the case and control groups. 
WES single variant analysis: Single variants were tested for association with DKD (N cases=481, N controls=479) 
and ESRD (N cases=168, N controls=479) using the logistic score test 42 implemented in Epacts, with sex and two 
principal components as covariates. Related individuals, monomorphic SNPs and those with standard error greater 
than 10 were excluded from the analysis. While the study setting provided low statistical power to detect rare 
variants with exome-wide significance (p<9×10-8 to correct for 530,776 tested variants) in line with previous reports 
on the statistical power to detect rare variants 43, we had sufficient power (80%) to detect a low frequency variant 
(MAF=0.05) with a large OR of 5.65 (Supplemental Figure 13).  
WES gene-based analysis: We applied three series of gene based tests: a burden test (VT) 44 that assumes the 
direction of effect of grouped variants is the same, a dispersion test (SKAT) 45 that performs well when the direction 
of variant effect differs, and a hybrid (SKAT-O) 46 that uses multiple methods in a single test. Only unrelated 
individuals were included in the analysis and sex and principal components were used as covariates to adjust for 
population structure. For all three tests we grouped variants into four categories using the same procedure as 
described in Mahajan et al. 47, were variants were categorized as either protein truncating (PTV; e.g. nonsense, 
frameshift, essential splice site), deleterious protein altering variants (e.g. missense, in-frame indel, and non-essential 
splice-site variants predicted to be deleterious, further sub-divided into “strict” and “broad” grouping if predicted 
deleterious by all five/ at least one annotation algorithm (Polyphen2-HumDiv, PolyPhen2-HumVar, LRT, 
MutationTaster and SIFT), respectively, as described by Purcell et al. 48, and any protein altering variants (e.g. 
missense, in-frame indel, non-essential splice-site) if predicted to be so by at least one of three annotation algorithms 
(snpEff, CHAos and VEP). These four groups are referred to as 1) PTV-only, 2) PTV+strict, 3 ) PTV+broad, and 4) 
PTV+missense, from the strictest to the most permissive class. A MAF threshold of 1% was applied to the more 
permissive masks PTV+missense and PTV+broad to exclude common variants from the WES analysis.  
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WES gene set enrichment analysis: We were interested in seeing whether we could find any signals in common 
with GWAS and WES association data, as well as detect enrichment for specific gene-sets. A total of 43 gene sets 
were created, based on top findings from the GWAS analyses, kidney-related functional terms in public databases, 
text mining approaches and kidney gene expression. These gene sets were analysed for enrichment in WES 
association results (obtained with SKAT-O using the four different masks described above) using the GSEA method 
with SKAT-O’s p-value as the ranking statistic49. We applied permutations to the enriched gene sets to verify whether 
this enrichment was greater than expected by chance, by randomly assigning case/control status to the samples prior 
to re-analysing them with SKAT-O (using the same parameter settings as applied to the real data). This was repeated 
100 times for each of the enriched gene sets, noting the number of times the top finding in the permuted data had a 
better enrichment score than the candidate geneset in the real data. Since both of the enriched gene sets were 
derived from GWAS data, which included some of the WES samples, we removed overlapping samples and re-created 
the gene-sets and repeated the GSEA analysis. 
Bivariate analysis of GWAS and WES data: We applied ABACUS50 to the individual GWAS discovery cohorts 
(FinnDiane, EURODIAB, SDR, NFS-ORPS) on each of the seven different case-control phenotypes. In addition, ABACUS 
was applied to the WES cohorts (FinnDiane, Steno and SDR) on the ‘Late DKD’ and ‘ESRD vs. no DKD’ phenotypic 
comparisons as in the main WES analysis. For the SNP-sets definition we used REACTOME, KEGG and GO Biological 
Process, as defined in MSigDB database (sets c2 and c5) after mapping SNPs to genes according to the Illumina 
HumanOmniExpress.12v1_J gene annotation file. In order to analyse non-annotated SNPs/genes, we also defined 
SNP-sets of continuous 3,000 SNPs within each chromosome. Functional clustering of the ABACUS results was 
performed with DAVID software51,52.  
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SUPPLEMENTAL TABLES 
Supplemental Table 1: Proportion of phenotypic variance explained by the GWAS genotypes in 
FinnDiane, estimated with GCTA 
Phenotype Prevalence N Adj V(G)/V(p) SE V(G)/V(p) V(G)/V(p_L) SE V(G)/V(p_L) P 
Combined DKD 0.3 2,843 no 0.24 0.10 0.35 0.15 6.4E-03 
Combined DKD 0.3 2,843 yes 0.34 0.10 0.50 0.15 2.5E-04 
Late DKD 0.2 2,495 no 0.32 0.11 0.43 0.15 1.3E-03 
Late DKD 0.2 2,495 yes 0.51 0.12 0.67 0.15 2.0E-06 
ESRD vs. no DKD 0.1 1,985 no 0.38 0.14 0.47 0.18 3.4E-03 
ESRD vs. no DKD 0.1 1,985 yes 0.54 0.15 0.68 0.18 7.5E-05 
ESRD vs. non-ESRD 0.1 2,843 no 0.31 0.10 0.51 0.17 1.2E-03 
ESRD vs. non-ESRD 0.1 2,843 yes 0.34 0.10 0.57 0.17 4.7E-04 
CKD 0.3 2,595 no 0.28 0.11 0.47 0.18 4.2E-03 
CKD 0.3 2,595 yes 0.39 0.11 0.65 0.19 1.5E-04 
CKD+DN 0.2 1,949 no 0.42 0.14 0.59 0.20 1.1E-03 
CKD+DN 0.2 1,949 yes 0.59 0.15 0.84 0.20 9.8E-06 
Early DKD 0.1 1,820 no 0.02 0.16 0.02 0.24 0.46 
Early DKD 0.1 1,820 yes 0.03 0.16 0.04 0.24 0.43 
Prevalence: Estimated prevalence of the cases in the T1D, employed for transforming the results for the underlying 
T1D population. Adj: no, model unadjusted; yes: model adjusted for sex, diabetes duration, and age at diabetes 
onset. V(G)/V(p) proportion of phenotypic variance explained by the genotypes, i.e. heritability, as observed in the 
study population. SE: standard error. V(G)/V(p_L): proportion of phenotypic variance explained by the genotypes, i.e. 
heritability, transformed for the underlying population scale.  
Prevalences were estimated as a combination of the following data: 
Microalbuminuria or worse: Cumulative incidence of persistent  micro-albuminuria was 33,6% (95% confidence 
interval 27.2% to 40.0%; median follow-up 18-years) in Hovind P. et al., BMJ 2004 53 
Macroalbuminuria or worse: Cumulative incidence of persistent macroalbuminuria was 14.6% (8.9% to 20.3%; 
Median follow-up 18 years) in Hovind P. et al., BMJ 2004 53 
ESRD: 40-year Cumulative risk of ESRD was 23.0% in Harjutsalo V. et al., Diabetologia 2011 54  
CKD (eGFR≤60 ml/min/1.73m
2
): The 16-year cumulative incidence of CKD was 31.7 percent in Shankar A et al., Exp 
Clin Endocrinol Diabetes 2007 55 
CKDDN: All patients with ESRD, plus patients with macroalbuminuria and eGFR<45 ml/min/1.73m2. 
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Supplemental Table 2: Information on genotyping, and clinical characteristics of the discovery and 
replication patients divided based on the seven case – control definitions 
Supplemental Table 2 can be found on the Supplemental Excel sheet. 
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Supplemental Table 3: Number of subjects included in the analysis in the discovery and in silico replication cohorts  
 Phenotype   Stage 1: Discovery GWAS Stage 2: In silico replication Total 
Stages 
1+2   
criteria 
Cohort FinnDiane EURODIAB SDR NFS-ORPS Total UK-ROI GoKinD US French/Danish DCCT/EDIC Joslin Total  
   N total 3,415 789 556 396 5,156 1,726 1,595 1,415 1,271 1,073 7,095 12,251 
Combined DKD total 3,415 789 556 396 5,156 1,726 1,595 1,430 1,271 1,073 7,095 12,251 
 
miA/maA/ESRD case 1,802 298 266 197 2,563 823 774 691 551 349 3,188 5,751 
  noA control 1,613 491 290 199 2,593 903 821 739 720 724 3,907 6,500 
Early DKD total 2,076 586 382 349 3,393  – –  931 1,130  – 2,061 5,454 
 
miA case 463 95 92 150 800 – – 192 410 – 602 1,402 
 
noA control 1,613 491 290 199 2,593 – – 739 720 – 1,459 4,052 
Late DKD total 2,952 694 458 246 4,350 1,726 1,595 1,188 861 1,073 6,443 6,878 
 
maA/ESRD case 1,339 203 168 47 1,757 823 774 449 141 349 2,536 4,293 
 
noA control 1,613 491 290 199 2,593 903 821 739 720 724 3,907 6,500 
ESRD vs. no DKD total 2,267 575 365  – 3,207 1,149 1,329 811  – 862 4,151 7,358 
 
ESRD case 654 84 75 – 813 246 508 72 – 138 964 1,777 
 
noA control 1,613 491 290 – 2,394 903 821 739 – 724 3,187 5,581 
 ESRD vs. non-ESRD total 3,415 789 604  – 4,808 1,687 1,595 1,415  – 1,073 5,770 5,385 
 
ESRD case 654 84 75 – 813 246 508 72 – 138 964 1,777 
 
noA/miA/maA control 2,761 705 529 – 3,995 1,441 1,087 1,343 – 935 4,806 8,801 
 CKD total 3,056 580 528  – 4,164 1,274 1,586 1,421 1,266 1,048 6,595 10,759 
 
eGFR<60 case 979 113 163 – 1,255 668 710 391 79 198 2,046 3,301 
 
eGFR>60 control 2,077 467 365 – 2,909 606 876 1,030 1,187 850 4,549 7,458 




case 789 210 118 – 1,117 316 635 162 – 153 1,266 
2,383 
 
eGFR>60 AND noA control 1,422 357 239 – 2,018 523 784 674 – 674 2,655 4,673 
miA: microalbuminuria. maA: Macroalbuminuria. noA: normal albuminuria.  
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Supplemental Table 4: Statistical power to detect association with ‘combined DKD’ with genome-wide 
significance (p<5×10-8) at the discovery stage. 
      Risk Allele frequency 
OR RR (Aa) RR (AA) 0.01 0.05 0.10 0.20 0.50 
1.10         1.07            1.14    0.00 0.00 0.00 0.00 0.00 
1.2         1.13            1.28    0.00 0.00 0.00 0.04 0.16 
1.3         1.19            1.42    0.00 0.00 0.00 0.04 0.16 
1.4         1.25            1.56    0.00 0.05 0.39 0.90 1.00 
1.5         1.30            1.70    0.00 0.17 0.76 1.00 1.00 
1.55         1.33            1.77    0.00 0.30 0.90 1.00 1.00 
1.6         1.36            1.84    0.00 0.46 0.97 1.00 1.00 
2.0         1.54            2.37    0.03 0.99 1.00 1.00 1.00 
RR: Relative Risk, calculated as RR = OR/((1-prev)+(prev x OR)), where prev is the incidence in non-carrier 
group, assumed to be 30% for the Combined DKD phenotype. RR (AA) was calculated as RR(Aa)^2 
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Supplemental Table 5: Association analysis results for the 101 GWAS SNPs selected for in silico replication.  
Supplemental Table 5 can be found on the Supplemental Excel sheet. 
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Supplemental Table 6: Statistical power to detect association with ‘Combined DKD’ with genome-wide 
significance (p<5x10
-8
) with the two-stage study design. 
      Risk allele frequency 
OR RR (Aa) RR (AA) 0.01 0.05 0.10 0.20 0.30 0.40 0.50 
1.10    1.07 1.14 0 0 0 0 0 0.01 0.01 
1.2 1.13 1.28 0 0 0.01 0.09 0.19 0.25 0.25 
1.3 1.19 1.42 0 0.02 0.17 0.57 0.78 0.84 0.83 
1.4 1.25 1.56 0 0.13 0.57 0.95 0.99 0.99 0.99 
1.47 1.29 1.66 
  
0.80 
    1.5 1.30 1.70 0 0.33 0.87 1 1 1 1 
2 1.54 2.37 0.09 1 1 1 1 1 1 
RR: Relative Risk, calculated as RR = OR/((1-prev)+(prev x OR)), where prev is the incidence in non-carrier group, 
assumed to be 30% for the Combined DKD phenotype.  
RR (AA) was calculated as RR(Aa)2 
Power calculations were performed with Power Calculator for Two Stage Association Studies (CaTS; 
http://csg.sph.umich.edu//abecasis/cats/) 
Parameters used in the calculations: 
N= 5,751 cases, 6,500 controls; 42% of samples genotyped in stage 1  
11/ 8,578,867 = 0.000128% of markers genotyped at stage 2 
Significance level: p=5×10-8 
Prevalence: 30% 
Additive genetic model 
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Supplemental Table 7: Association at the AFF3 locus with ‘ESRD vs. non-ESRD’ phenotypic comparison, 
conditional on the previously reported lead SNP rs7583877 
          Raw results Conditional on the other SNP 
Chr SNP bp refA freq Beta se p Beta se p 
2 rs7583877 100460654 T 0.71 -0.26 -0.06 8.71E-05 0.01 0.04 0.78 
2 rs7562121 100384354 G 0.77 -0.38 -0.07 8.92E-08 -0.16 0.04 1.97E-04 
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Supplemental Table 8: Statistical power to detect association with the ‘Late DKD’ phenotype for varying 
odds ratio and risk allele frequency. 
Power to detect association with p<0.05 
       Risk allele Frequency 
OR RR (Aa) RR (AA) 0.05 0.10 0.20 0.50 
1.10 1.08 1.16 0.17 0.27 0.42 0.56 
1.2 1.15 1.33 0.45 0.71 0.91 0.98 
1.25 1.19 1.42 0.63 0.88 0.99 1.00 
1.3 1.23 1.50 0.79 0.96 1.00 1.00 
1.4 1.30 1.68 0.95 1.00 1.00 1.00 
1.5 1.36 1.86 0.99 1.00 1.00 1.00 
2 1.67 2.78 1.00 1.00 1.00 1.00 
2.5 1.92 3.70 1.00 1.00 1.00 1.00 
Power to detect association with p<1.1×10
-3
 (correction for multiple testing) 
      Risk allele Frequency 
OR RR (Aa) RR (AA) 0.05 0.10 0.20 0.50 
1.10            1.08            1.16    0.01 0.03 0.07 0.13 
1.2         1.15            1.33    0.08 0.23 0.53 0.79 
1.3         1.23            1.50    0.31 0.69 0.95 0.99 
1.4         1.30            1.68    0.62 0.94 1.00 1.00 
1.5         1.36            1.86    0.84 0.99 1.00 1.00 
2         1.67            2.78    1.00 1.00 1.00 1.00 
2.5         1.92            3.70    1.00 1.00 1.00 1.00 
RR: Relative Risk, calculated as RR = OR/((1-prev)+(prev × OR)), where prev is the incidence in non-carrier 
group, assumed to be 20% for the Late DKD phenotype. RR(AA) was calculated as RR(Aa)2.  
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Supplemental Table 9: Evaluation of previously reported candidate genes or GWAS loci on kidney complications in type 1 and type 2 diabetes, or 
GWAS on CKD in the general population. 
      DKD Early DKD Late DKD ESRD vs. no DKD ESRD vs. non-ESR CKD CKD+DKD  
SNP GENE Source Type EA NEA EAF P OR EAF P OR EAF P OR EAF P OR EAF P OR EAF P OR EAF P OR Direction 
rs2838302 SIK1 Sambo 2014 GWAS, T1D-ESRD G A 0.08 0.81 1.04 0.08 0.25 0.9 0.08 0.32 1.09 0.08 0.0017 1.39 0.08 4.10E-05 1.56 0.08 0.0019 1.35 0.09 0.03 1.24 Same 
rs7583877 AFF3 Sandholm 2012 GWAS, T1D-ESRD T C 0.71 0.85 0.99 0.71 0.06 1.13 0.7 0.21 0.94 0.7 0.0044 0.81 0.71 8.70E-05 0.77 0.71 0.02 0.88 0.7 0.01 0.85 same 
rs17709344 RGMA-MCTP2 Sambo 2014 GWAS, T1D-ESRD A G 0.03 0.01 1.39 0.02 0.1 1.4 0.03 0.004 1.56 NA NA NA NA NA NA 0.02 0.01 1.56 0.03 8.20E-04 1.73 Same 
rs12437854 RGMA–MCTP2 Sandholm 2012 GWAS, T1D-ESRD G T 0.06 0.03 1.2 0.05 0.31 1.14 0.06 0.03 1.22 NA NA NA NA NA NA 0.06 0.01 1.33 0.06 0.0013 1.43 same 
rs12137135 WNT4-ZBTB40 Sambo 2014 GWAS, T1D-ESRD G A 0.16 0.95 1 0.16 0.39 0.94 0.16 0.72 1.02 0.16 0.05 1.21 0.16 0.01 1.28 0.16 0.04 1.18 0.16 0.23 1.08 Same 
rs1801282 PPARG Mooyaart 2011 CGM, T1D/T2D G C 0.15 0.13 1.08 0.14 0.95 0.98 0.15 0.07 1.12 0.15 0.05 1.16 0.16 0.02 1.18 0.15 0.01 1.18 0.15 0.05 1.16 
Opposite, 
NS 
rs12917114 SEMA6D-SLC24A5 Sambo 2014 GWAS, T1D-ESRD T C 0.13 0.39 0.97 0.12 0.15 0.9 0.13 0.81 1.01 0.13 0.15 1.18 0.13 0.01 1.27 0.13 0.07 1.18 0.13 0.24 1.12 same 
rs699 AGT Mooyaart 2011 CGM, T1D/T2D G A 0.43 0.14 1.07 0.43 0.01 1.17 0.42 0.67 1.02 0.42 0.49 1.04 0.43 0.74 0.98 0.43 0.59 0.98 0.43 0.98 1.01 
Opposite, 
NS 
rs1617640 EPO Tong 2008 CGM, T1D-DN A C 0.57 0.03 0.92 0.58 0.45 0.96 0.57 0.02 0.91 0.57 0.49 0.98 0.56 0.71 1 0.56 0.29 0.96 0.57 0.65 0.98 Opposite 
rs741301 ELMO1 Shimazaki 2005 GWAS, T2D-DN T C 0.68 0.54 0.96 0.68 0.69 1.02 0.67 0.34 0.94 0.67 0.04 0.86 0.68 0.02 0.86 0.67 0.3 0.93 0.67 0.31 0.93 Same 
rs7588550 ERBB4 Sandholm 2012 GWAS, T1D-DN A G 0.94 0.05 1.24 0.94 0.66 1.14 0.95 0.02 1.3 NA NA NA NA NA NA 0.94 0.05 1.25 0.94 0.03 1.34 same 
rs1670754 Chr 4p15.1 Sambo 2014 GWAS, T1D-ESRD A G 0.17 0.24 1.07 0.17 0.13 1.13 0.17 0.56 1.04 0.17 0.04 1.21 0.17 0.03 1.2 0.17 0.12 1.11 0.17 0.04 1.16 Same 
rs1041466 Chr 13q Pezzolesi 2009 GWAS, T1D-DN G A 0.47 0.54 1.01 0.47 0.86 0.97 0.48 0.38 1.02 0.48 0.09 1.09 0.48 0.03 1.12 0.48 0.14 1.07 0.48 0.64 1.02 same 
rs1799987 CCR5 Mooyaart 2011 CGM, T1D/T2D G A 0.45 0.46 1.04 0.45 0.49 1.05 0.45 0.55 1.04 0.45 0.5 1.07 0.45 0.54 1.06 0.45 0.95 1.01 0.45 0.09 1.11  
rs5186 AGTR1 Mooyaart 2011 CGM, T1D/T2D C A 0.24 0.11 1.1 0.24 0.57 1.06 0.23 0.21 1.1 0.23 0.93 1.01 0.23 0.82 1 0.23 0.38 0.94 0.24 0.49 1.05  
rs11993333 PVT1 Mooyaart 2011 CGM, T1D/T2D C T 0.53 0.25 1.05 0.53 0.91 1.02 0.53 0.12 1.07 0.53 0.81 1.02 0.53 0.89 1 0.53 0.83 1.02 0.53 0.37 1.06  
rs833061 VEGFA Mooyaart 2011* CGM, T1D/T2D T C 0.48 0.12 1.07 0.48 0.42 1.05 0.48 0.15 1.07 0.48 0.32 1.07 0.48 0.6 1.04 0.48 0.31 1.05 0.48 0.12 1.1  
rs9298190 LOC100132891 Craig 2009 
Pooled GWAS on 
T1D-ESRD 
C T 0.39 0.49 1.03 0.39 0.83 0.99 0.39 0.21 1.06 0.39 0.15 1.09 0.39 0.12 1.09 0.39 0.53 1.04 0.39 0.49 1.04 
 
rs1564939 GLRA3 Sandholm 2014 GWAS, T1D-AER C T 0.19 0.26 1.07 0.19 0.61 1.03 0.19 0.27 1.08 0.18 0.37 1.1 0.18 0.47 1.08 0.18 0.24 1.11 0.19 0.13 1.13  
rs2268388 ACACB Mooyaart 2011 CGM, T1D/T2D A G 0.15 0.9 1 0.15 0.23 0.92 0.15 0.62 1.04 0.15 0.21 1.11 0.15 0.13 1.12 0.15 0.49 1.05 0.15 0.54 1.05  
rs2070744 NOS3 Mooyaart 2011* CGM, T1D/T2D T C 0.62 0.22 1.05 0.61 0.84 1.01 0.62 0.14 1.07 0.62 0.53 1.06 0.63 0.58 1.04 0.62 0.16 1.08 0.61 0.27 1.08  
rs7805747 PRKGA2 Köttgen 2010 GWAS CKD A G 0.23 0.14 0.94 0.24 0.16 0.91 0.23 0.37 0.97 0.23 0.87 1.02 0.22 0.58 1.04 0.22 0.21 1.07 0.23 0.6 1.03  
rs1749824 ZMIZ1 Craig 2009 
Pooled GWAS on 
T1D-ESRD 
A C 0.43 0.31 0.96 0.43 0.29 0.94 0.43 0.44 0.97 0.44 0.47 0.96 0.44 0.83 0.99 0.44 0.14 0.94 0.44 0.42 0.96 
 
rs10011025 GLRA3 Sandholm 2014 GWAS, T1D-AER G A 0.18 0.31 1.07 0.18 0.69 1.02 0.18 0.32 1.09 0.18 0.37 1.11 0.18 0.45 1.08 0.18 0.29 1.1 0.18 0.14 1.13  
rs2106294 LIMK2  McDonough 2010 
GWAS on T2D-DN 
AA 
T C 0.68 0.46 1.04 0.69 0.27 1.08 0.68 0.61 1.03 0.67 0.84 0.97 0.68 0.14 0.94 0.68 0.34 0.96 0.68 0.83 1.01 
 
rs6492208 Chr 13q Pezzolesi 2009 GWAS, T1D-DN C T 0.39 0.59 0.99 0.39 0.85 1.01 0.39 0.55 0.99 0.38 0.19 0.94 0.39 0.16 0.94 0.38 0.41 0.97 0.39 0.99 1  
rs1888747 FRMD3 Pezzolesi 2009 GWAS, T1D-DN G C 0.7 0.78 1 0.7 0.95 1 0.7 0.6 1.02 0.7 0.17 1.11 0.7 0.34 1.07 0.71 0.96 1 0.7 0.49 1.04  
rs1129456 GREM1 Mooyaart 2011* CGM, T1D/T2D T A 0.12 0.38 1.06 0.12 0.47 0.95 0.13 0.18 1.1 0.12 0.55 1.04 0.13 0.86 0.99 0.13 0.86 1.01 0.13 0.89 1.01  
rs7989848 Chr 13q Pezzolesi 2009 GWAS T1D-DN A G 0.56 0.62 1.01 0.56 0.97 0.99 0.56 0.51 1.02 0.56 0.22 1.06 0.56 0.19 1.06 0.56 0.36 1.04 0.56 0.58 1.03  
rs10868025 FRMD3 Pezzolesi 2009 GWAS T1D-DN G A 0.36 0.62 0.98 0.37 0.91 1 0.36 0.38 0.96 0.36 0.2 0.92 0.36 0.34 0.94 0.36 0.75 0.99 0.36 0.29 0.94  
rs16864170 SOX11 Köttgen 2010 GWAS CKD C T 0.04 0.89 1.03 0.04 0.22 0.82 0.05 0.31 1.12 0.04 0.6 1.07 0.04 0.53 1.09 0.04 0.94 0.99 0.04 0.69 0.95  
rs13293564 UNC13B Mooyaart 2011* CGM, T1D/T2D T G 0.44 0.76 1.01 0.43 0.25 0.94 0.45 0.33 1.04 0.45 0.33 1.05 0.45 0.51 1.03 0.45 0.66 1.02 0.44 0.73 0.96  
rs1411766 NA Pezzolesi 2009 GWAS T1D-DN A G 0.36 0.27 0.95 0.37 0.26 0.92 0.37 0.46 0.96 0.37 0.7 1.02 0.36 0.32 1.06 0.37 0.78 1.02 0.37 0.93 1  
rs39075 CPVL/CHN2 Pezzolesi 2009 GWAS T1D-DN A G 0.39 0.34 0.96 0.39 0.27 0.94 0.39 0.59 0.97 0.4 0.83 0.99 0.39 0.76 1.02 0.39 0.65 1.02 0.4 0.76 1.01  
rs9521445 Chr 13q Pezzolesi 2009 GWAS T1D-DN A C 0.51 0.39 1.03 0.52 0.32 1.06 0.51 0.65 1.02 0.51 0.72 1.01 0.51 0.94 0.99 0.51 0.86 1 0.51 0.96 1  
rs739401 CARS Pezzolesi 2009 GWAS T1D-DN T C 0.43 0.34 1.05 0.44 0.43 1.06 0.43 0.54 1.03 0.42 0.76 1.03 0.42 0.94 1.01 0.43 0.66 0.98 0.43 0.64 1.03  
rs451041 CARS Pezzolesi 2009 GWAS T1D-DN G A 0.43 0.38 1.05 0.44 0.51 1.05 0.43 0.53 1.03 0.42 0.98 1.01 0.42 0.82 1 0.43 0.57 0.97 0.43 0.72 1.02  
rs17300539 ADIPOQ Mooyaart 2011, CGM, T1D/T2D A G 0.05 0.67 1.06 0.06 0.45 1.09 0.05 0.96 1.02 0.05 0.57 1.11 0.05 0.5 1.11 0.05 0.43 1.08 0.06 0.75 1.05  
rs2410601 PSD3-SH2D4A Sandholm 2014 GWAS T1D-AER C G 0.57 0.87 0.98 0.56 0.44 0.93 0.57 0.86 1 0.57 0.9 1 0.57 0.7 1.02 0.57 0.64 1.02 0.57 0.45 0.95  
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rs6930576 SASH1  McDonough 2010 GWAS T2D-DN AA A G 0.34 0.59 1.04 0.34 0.72 1.04 0.34 0.91 1.02 0.33 0.67 1 0.33 0.47 0.97 0.33 0.56 0.98 0.34 0.74 0.98  
rs3767140 HSPG2 Mooyaart 2011* CGM, T1D/T2D A C 0.23 0.81 1.02 0.22 0.74 1.03 0.23 0.81 1 0.23 0.79 1.02 0.23 0.88 1 0.22 0.47 1.04 0.22 0.84 0.99  
rs39059 CPVL/CHN2 Pezzolesi 2009 GWAS T1D-DN G A 0.36 0.48 0.96 0.36 0.66 0.97 0.36 0.52 0.96 0.36 0.67 0.99 0.36 0.92 1 0.36 1 1 0.37 0.96 0.99  
rs12917707 UMOD Köttgen 2010 GWAS CKD T G 0.22 0.71 0.99 0.22 0.74 1.02 0.22 0.64 0.98 0.22 0.85 1.01 0.22 0.97 1.02 0.22 0.57 0.97 0.22 0.59 0.96  
rs2358944 MSRB3-HMGA2  McDonough 2010 GWAS T2D-DN AA A G 0.84 0.66 0.98 0.84 0.82 0.98 0.84 0.66 0.97 0.84 0.8 0.98 0.84 0.92 0.99 0.84 0.8 0.99 0.84 0.75 0.99  
rs7769051 RPS12 McDonough 2010 GWAS T2D-DN AA A C 0.14 0.89 1 0.14 0.86 0.98 0.14 0.77 0.99 0.14 0.68 0.98 0.14 0.89 1 0.14 0.89 1 0.15 0.94 1.01  
rs841853 GLUT1 Mooyaart 2011* CGM, T1D/T2D C A 0.69 0.74 1.01 0.68 0.93 0.99 0.69 0.72 1.01 0.68 0.93 0.99 0.69 0.71 0.97 0.68 0.8 1 0.67 0.75 0.97  
Results excluding the FinnDiane patients for SNPs were the source publication includes FinnDiane patients 
SNP GENE Source Type EA NEA EAF OR P EAF OR P EAF OR P EAF OR P EAF OR P EAF OR P EAF OR P Direction 
rs13293564 UNC13B Mooyaart 2011* CGM, T1D/T2D T G 0.41 0.83 0.03 0.42 0.80 0.02 0.42 0.83 0.11 0.43 0.93 0.87 0.42 1.00 0.78 0.42 0.88 0.31 0.42 0.77 0.02 Opposite 
rs2838302 SIK1 Sambo 2014 GWAS, T1D-ESRD G A 0.09 1.23 0.22 0.08 1.20 0.55 0.09 1.27 0.14 0.08 1.52 0.04 0.09 1.39 0.09 0.09 1.22 0.28 0.09 1.19 0.33 same 
rs12137135 WNT4-ZBTB40 Sambo 2014 GWAS, T1D-ESRD G A 0.15 0.81 0.04 0.16 0.89 0.29 0.16 0.76 0.04 0.17 0.81 0.11 0.16 0.91 0.32 0.15 0.97 0.62 0.15 0.77 0.08 Opposite 
rs699 AGT Mooyaart 2011 CGM, T1D/T2D G A 0.43 1.09 0.33 0.43 1.24 0.05 0.42 0.98 0.79 0.43 1.08 0.59 0.43 1.08 0.67 0.43 0.98 0.65 0.43 1.00 0.74 
 rs7583877 AFF3 Sandholm 2012 GWAS, T1D-ESRD T C 0.66 1.12 0.19 0.66 1.21 0.07 0.66 1.08 0.72 0.66 1.07 0.49 0.66 1.03 0.89 0.67 1.03 0.98 0.66 1.03 0.83 
 rs5186 AGTR1 Mooyaart 2011 CGM, T1D/T2D C A 0.30 1.17 0.10 0.29 1.08 0.71 0.30 1.21 0.11 0.28 1.10 0.86 0.29 1.07 0.96 0.30 0.94 0.78 0.30 1.17 0.08 
 rs1801282 PPARG Mooyaart 2011 CGM, T1D/T2D G C 0.11 1.18 0.10 0.11 1.20 0.20 0.11 1.18 0.18 0.11 1.31 0.11 0.12 1.18 0.24 0.12 1.12 0.23 0.12 1.08 0.47 
 rs7588550 ERBB4 Sandholm 2012 GWAS, T1D-DN A G 0.96 0.92 0.57 0.96 0.71 0.10 0.96 1.00 0.95 NA NA NA NA NA NA NA NA NA NA NA NA 
 rs1799987 CCR5 Mooyaart 2011 CGM, T1D/T2D G A 0.45 1.09 0.65 0.46 1.21 0.11 0.45 1.03 0.74 0.44 1.02 0.63 0.45 0.97 0.36 0.44 0.99 0.56 0.45 1.17 0.22 
 rs12917114 SEMA6D-SLC24A5 Sambo 2014 GWAS, T1D-ESRD T C 0.08 0.86 0.13 0.08 0.87 0.27 0.08 0.86 0.24 0.07 0.94 0.68 0.07 1.05 0.94 0.07 1.08 0.98 0.07 0.94 0.74 
 rs1564939 GLRA3 Sandholm 2014 GWAS, T1D-AER C T 0.22 0.92 0.34 0.22 0.94 0.82 0.22 0.90 0.27 0.21 0.82 0.13 0.21 0.84 0.19 0.20 1.02 0.79 0.20 0.92 0.39 
 rs10011025 GLRA3 sandholm 2014 GWAS, T1D-AER G A 0.21 0.92 0.32 0.21 0.92 0.69 0.21 0.91 0.27 0.20 0.83 0.14 0.20 0.85 0.21 0.20 0.98 0.61 0.19 0.91 0.33 
 rs12437854 RGMA–MCTP2 Sandholm 2012 GWAS, T1D-ESRD G T 0.06 1.03 0.73 0.06 1.15 0.47 0.06 0.95 0.99 NA NA NA NA NA NA NA NA NA 0.06 1.29 0.19 
 rs2410601 PSD3-SH2D4A Sandholm 2014 GWAS T1D-AER C G 0.53 1.05 0.41 0.53 0.95 0.92 0.54 1.10 0.31 0.54 1.03 0.83 0.54 1.02 0.86 0.54 0.98 0.96 0.54 0.89 0.25 
 rs1670754 Chr 4p15.1 Sambo 2014 GWAS, T1D-ESRD A G 0.20 0.96 0.82 0.21 1.09 0.46 0.20 0.89 0.32 0.20 1.00 0.90 0.20 0.98 0.76 0.20 0.97 0.93 0.20 1.13 0.25 
 N subjects       
  
Case Ctrl Total Case Ctrl Total Case Ctrl Total Case Ctrl Total Case Ctrl Total Case Ctrl Total Case Ctrl Total   
SDR + Eurodiab + Cambridge 761 980 1,741 337 980 1,317 418 980 1,398 159 781 940 159 1,234 1,393 276 832 1,108 328 596 924   
Direction: Direction of effect compared between this and the original study; Opposite, NS: Association was non-significant in the previous meta-analysis, 
trending in the opposite direction. CGM: meta-analysis of candidate gene studies. P-value required for statistical significance after adjustment for multiple 
testing is 0.0011 (significance level α=0.05, 46 loci), highlighted with green background and bold text. *Variant was significant in the literature-based meta-
analysis 56. Source: Sambo 2014 57; Sandholm 2012 2; Mooyaart 2011 56; Tong 2008 58; shimazaki 2005 59; Pezzolesi 2009 60; Craig 2009 61; Sandholm 2014 62; 
Köttgen 2010 63; McDonough 2010 64. 
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Supplemental Table 10: Association between diabetic kidney complications and genetic risk scores of 
related phenotypes  
DKD phenotype trait OR 95% CI P-value 
Late DKD Body mass index (z transformed) 2,51 1,64 - 3,84 2,20E-05 
Late DKD Body mass index (BMI) 2,06 1,37 - 3,07 4,50E-04 
ESRD vs. no DKD Body mass index (BMI) 2,52 1,49 - 4,26 5,40E-04 
Combined DKD Type 2 diabetes (inclu. lipid SNPs) 1,28 1,11 - 1,47 6,10E-04 
Combined DKD Body mass index (z transformed) 1,92 1,32 - 2,78 6,30E-04 
CKD Body mass index (BMI) 2,04 1,33 - 3,13 1,00E-03 
CKD Body mass index (z transformed) 2,04 1,33 - 3,14 1,10E-03 
Late DKD Type 2 diabetes (inclu. lipid SNPs) 1,28 1,1 - 1,5 1,90E-03 
Combined DKD Type 2 diabetes 1,19 1,07 - 1,32 1,90E-03 
ESRD vs. no ESRD Body mass index (BMI) 2,1 1,3 - 3,39 2,50E-03 
Late DKD Type 2 diabetes 1,21 1,07 - 1,36 2,80E-03 
Combined DKD Type 2 diabetes (inclu. glycaemic SNPs) 1,18 1,05 - 1,32 5,60E-03 
Late DKD Fasting proinsulin (BMI+FG adj.) 2,78 1,35 - 5,72 5,70E-03 
CKD and DKD Body mass index (BMI) 1,92 1,2 - 3,09 6,90E-03 
ESRD vs. no DKD Body mass index (z transformed) 2,03 1,2 - 3,44 8,30E-03 
ESRD vs. no DKD Type 2 diabetes (inclu. lipid SNPs) 1,32 1,07 - 1,63 8,30E-03 
CKD and DKD Low-density lipoprotein C 1,79 1,15 - 2,79 9,70E-03 
Late DKD Type 2 diabetes (inclu. glycaemic SNPs) 1,18 1,04 - 1,34 1,30E-02 
CKD and DKD Type 2 diabetes 1,19 1,03 - 1,37 1,70E-02 
Late DKD Waist-Hip Ratio (BMI adj.) 1,76 1,1 - 2,79 1,80E-02 
CKD and DKD Body mass index (z transformed) 1,77 1,09 - 2,86 2,00E-02 
Combined DKD Body mass index (BMI) 1,52 1,06 - 2,17 2,10E-02 
Combined DKD Fasting proinsulin (BMI+FG adj.) 2,13 1,11 - 4,09 2,20E-02 
CKD and DKD Type 2 diabetes (inclu. glycaemic SNPs) 1,19 1,02 - 1,38 2,70E-02 
CKD and DKD Type 2 diabetes (inclu. lipid SNPs) 1,21 1,01 - 1,46 4,00E-02 
Late DKD Insulin resistance 13,96 1,12 - 174,72 4,10E-02 
Early DKD Type 2 diabetes (inclu. glycaemic SNPs) 1,18 1 - 1,39 4,50E-02 
Early DKD Type 2 diabetes (inclu. lipid SNPs) 1,22 1 - 1,49 4,70E-02 
CKD Waist-Hip Ratio (BMI adj.) 1,65 1,01 - 2,71 4,80E-02 
Early DKD Type 2 diabetes 1,16 1 - 1,36 5,30E-02 
Combined DKD Insulin resistance 9,11 0,95 - 87,3 5,50E-02 
ESRD vs. no ESRD Type 2 diabetes (inclu. lipid SNPs) 1,2 0,99 - 1,45 6,30E-02 
CKD Fasting proinsulin (BMI+FG adj.) 2,07 0,95 - 4,5 6,60E-02 
ESRD vs. no DKD Type 2 diabetes 1,16 0,99 - 1,36 7,10E-02 
Early DKD Fasting glucose (BMI adj.) 4,71 0,86 - 25,96 7,50E-02 
ESRD vs. no DKD Low-density lipoprotein C 1,58 0,95 - 2,61 7,70E-02 
Late DKD ln(Fasting insulin) BMI adj. 5,53 0,83 - 37,02 7,80E-02 
ESRD vs. no DKD High-density lipoprotein C 1,95 0,91 - 4,15 8,40E-02 
Early DKD Insulin resistance 15,17 0,61 - 376,25 9,70E-02 
ESRD vs. no DKD Type 2 diabetes (inclu. glycaemic SNPs) 1,15 0,97 - 1,36 1,00E-01 
ESRD vs. no ESRD Low-density lipoprotein C 1,49 0,92 - 2,4 1,00E-01 
Combined DKD ln(Fasting insulin) BMI adj. 4,07 0,74 - 22,36 1,10E-01 
Early DKD Low-density lipoprotein C 1,51 0,91 - 2,5 1,10E-01 
ESRD vs. no DKD Systolic blood pressure 0,45 0,17 - 1,19 1,10E-01 
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DKD phenotype trait OR 95% CI P-value 
CKD and DKD Waist-Hip Ratio (BMI adj.) 1,56 0,9 - 2,71 1,10E-01 
CKD and DKD Fasting proinsulin (BMI+FG adj.) 1,96 0,85 - 4,5 1,10E-01 
CKD Systolic blood pressure 0,53 0,23 - 1,19 1,20E-01 
CKD Type 2 diabetes (inclu. glycaemic SNPs) 1,11 0,97 - 1,28 1,30E-01 
Early DKD ln(Fasting insulin) BMI adj. 6,39 0,57 - 72,23 1,30E-01 
ESRD vs. no ESRD Body mass index (z transformed) 1,43 0,89 - 2,29 1,40E-01 
Combined DKD Fasting glucose (BMI adj.) 2,45 0,75 - 8 1,40E-01 
Combined DKD Waist-Hip Ratio (BMI adj.) 1,37 0,9 - 2,06 1,40E-01 
ESRD vs. no ESRD High-density lipoprotein C 1,69 0,84 - 3,38 1,40E-01 
CKD Type 2 diabetes (inclu. lipid SNPs) 1,13 0,96 - 1,34 1,40E-01 
Late DKD High-density lipoprotein C 1,52 0,86 - 2,7 1,50E-01 
ESRD vs. no DKD Fasting proinsulin (BMI+FG adj.) 1,94 0,76 - 4,94 1,60E-01 
ESRD vs. no ESRD HbA1c 0,28 0,04 - 1,8 1,80E-01 
Late DKD 2hr-Glucose (BMI adj.) 0,75 0,49 - 1,15 1,90E-01 
CKD and DKD ln(Fasting insulin) BMI adj. 4,32 0,46 - 40,29 2,00E-01 
CKD and DKD Insulin resistance 6,99 0,36 - 135,72 2,00E-01 
CKD and DKD Systolic blood pressure 0,56 0,23 - 1,38 2,10E-01 
ESRD vs. no DKD HbA1c 0,29 0,04 - 2,14 2,30E-01 
Combined DKD High-density lipoprotein C 1,36 0,82 - 2,26 2,30E-01 
CKD and DKD Fasting glucose (BMI adj.) 2,65 0,53 - 13,22 2,40E-01 
CKD Type 2 diabetes 1,08 0,95 - 1,23 2,40E-01 
ESRD vs. no DKD Waist-Hip Ratio (BMI adj.) 1,43 0,77 - 2,67 2,60E-01 
ESRD vs. no DKD 2hr-Glucose (BMI adj.) 0,74 0,43 - 1,26 2,70E-01 
CKD and DKD Triglycerides 0,67 0,32 - 1,37 2,70E-01 
ESRD vs. no DKD ln(Fasting insulin) BMI adj. 3,84 0,34 - 42,91 2,80E-01 
Late DKD Systolic blood pressure 0,66 0,31 - 1,4 2,80E-01 
Early DKD Body mass index (BMI) 0,76 0,46 - 1,27 3,00E-01 
CKD and DKD High-density lipoprotein C 1,42 0,72 - 2,77 3,10E-01 
Combined DKD Low-density lipoprotein C 1,2 0,84 - 1,71 3,20E-01 
Late DKD HbA1c 0,46 0,1 - 2,21 3,30E-01 
ESRD vs. no ESRD 2hr-Glucose (BMI adj.) 0,8 0,48 - 1,31 3,70E-01 
ESRD vs. no ESRD Type 2 diabetes (inclu. glycaemic SNPs) 1,07 0,92 - 1,26 3,80E-01 
ESRD vs. no ESRD Systolic blood pressure 0,67 0,27 - 1,67 3,90E-01 
Late DKD Triglycerides 0,77 0,42 - 1,41 4,00E-01 
CKD Fasting glucose (BMI adj.) 0,54 0,13 - 2,26 4,00E-01 
CKD HOMA-B 0,57 0,15 - 2,17 4,10E-01 
CKD Low-density lipoprotein C 1,19 0,78 - 1,82 4,10E-01 
Late DKD Fasting glucose (BMI adj.) 1,73 0,46 - 6,47 4,10E-01 
CKD and DKD HOMA-IR 3,01 0,2 - 44,97 4,30E-01 
Combined DKD 2hr-Glucose (BMI adj.) 0,86 0,58 - 1,26 4,40E-01 
Early DKD Fasting proinsulin (BMI+FG adj.) 1,43 0,56 - 3,65 4,50E-01 
ESRD vs. no ESRD Type 2 diabetes 1,06 0,91 - 1,22 4,60E-01 
CKD High-density lipoprotein C 1,26 0,68 - 2,34 4,60E-01 
ESRD vs. no DKD Insulin resistance 3,4 0,13 - 90,6 4,60E-01 
Late DKD HOMA-IR 2,32 0,24 - 22,65 4,70E-01 
CKD 2hr-Glucose (BMI adj.) 1,18 0,74 - 1,86 4,90E-01 
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DKD phenotype trait OR 95% CI P-value 
CKD HOMA-IR 0,46 0,04 - 4,77 5,10E-01 
ESRD vs. no ESRD Insulin resistance 0,38 0,02 - 8,04 5,30E-01 
ESRD vs. no DKD Triglycerides 0,78 0,35 - 1,74 5,50E-01 
ESRD vs. no ESRD Triglycerides 0,8 0,38 - 1,69 5,60E-01 
Early DKD HOMA-B 0,63 0,13 - 3,03 5,60E-01 
Early DKD HbA1c 1,83 0,22 - 15,06 5,70E-01 
CKD and DKD Type 1 diabetes 0,98 0,93 - 1,04 5,80E-01 
ESRD vs. no ESRD Fasting proinsulin (BMI+FG adj.) 1,28 0,54 - 3,02 5,80E-01 
Combined DKD Systolic blood pressure 0,83 0,42 - 1,63 5,90E-01 
ESRD vs. no ESRD Waist-Hip Ratio (BMI adj.) 1,17 0,65 - 2,09 6,00E-01 
ESRD vs. no ESRD HOMA-IR 0,51 0,04 - 6,97 6,20E-01 
Combined DKD HOMA-IR 1,68 0,22 - 12,67 6,20E-01 
Early DKD Systolic blood pressure 0,79 0,3 - 2,04 6,20E-01 
ESRD vs. no ESRD HOMA-B 1,44 0,33 - 6,25 6,30E-01 
CKD Type 1 diabetes 0,99 0,94 - 1,04 6,80E-01 
Early DKD Body mass index (z transformed) 1,11 0,66 - 1,86 6,90E-01 
Combined DKD HbA1c 0,75 0,18 - 3,14 7,00E-01 
Early DKD High-density lipoprotein C 1,15 0,57 - 2,33 7,00E-01 
ESRD vs. no DKD HOMA-B 1,35 0,28 - 6,59 7,10E-01 
ESRD vs. no DKD Type 1 diabetes 0,99 0,94 - 1,05 7,30E-01 
CKD ln(Fasting insulin) BMI adj. 0,72 0,1 - 5,39 7,50E-01 
CKD HbA1c 1,31 0,23 - 7,44 7,60E-01 
CKD Triglycerides 0,9 0,46 - 1,76 7,60E-01 
ESRD vs. no ESRD Fasting glucose (BMI adj.) 0,78 0,15 - 4,13 7,80E-01 
CKD and DKD HOMA-B 0,81 0,19 - 3,49 7,80E-01 
CKD and DKD 2hr-Glucose (BMI adj.) 0,93 0,57 - 1,54 7,90E-01 
Early DKD Waist-Hip Ratio (BMI adj.) 1,08 0,6 - 1,95 7,90E-01 
Late DKD HOMA-B 1,17 0,34 - 3,98 8,00E-01 
ESRD vs. no ESRD ln(Fasting insulin) BMI adj. 1,31 0,14 - 12,29 8,10E-01 
ESRD vs. no DKD Fasting glucose (BMI adj.) 1,24 0,21 - 7,41 8,10E-01 
Early DKD 2hr-Glucose (BMI adj.) 1,06 0,61 - 1,86 8,30E-01 
ESRD vs. no ESRD Type 1 diabetes 1 0,94 - 1,05 8,70E-01 
Late DKD Type 1 diabetes 1 0,95 - 1,04 8,70E-01 
Combined DKD Type 1 diabetes 1 0,96 - 1,04 8,70E-01 
Early DKD Type 1 diabetes 1 0,95 - 1,06 8,80E-01 
Combined DKD HOMA-B 0,92 0,31 - 2,76 8,80E-01 
Combined DKD Triglycerides 0,96 0,56 - 1,65 8,80E-01 
CKD Insulin resistance 0,84 0,06 - 12,46 9,00E-01 
Early DKD Triglycerides 1,02 0,47 - 2,19 9,70E-01 
ESRD vs. no DKD HOMA-IR 0,96 0,05 - 17,34 9,80E-01 
Late DKD Low-density lipoprotein C 1 0,67 - 1,5 9,80E-01 
Early DKD HOMA-IR 0,99 0,06 - 17,58 1,00E+00 
CKD and DKD HbA1c 1 0,16 - 6,4 1,00E+00 
Significant p-values (p<2.6×10-3, α=0.05 Bonferroni corrected for the 19 examined traits) are highlighted with bold 
italics.  
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References for the SNPs included in the genetic risk scores (GRS): Waist-Hip-ratio (adjusted for body mass index [BMI], 
NSNPs=54)
26, BMI (untransformed, NSNPs=96 
27 and z-transformed, NSNPs=24 
28), systolic blood pressure (SBP, NSNPs=22)
29, 
low-density lipoprotein cholesterol (LDL-C, NSNPs=24), triglycerides (TRIG, NSNPs=20), high-density lipoprotein cholesterol 
(HDL-C, NSNPs=26)
30, T1D (NSNPs=51) 
31, T2D 32 (including all SNPs (NSNPs=70), and without any other effects other than on 
T2D or lipids (NSNPs=56)
30 and T2D or glycemic traits (NSNPs=62)
33,34), 2-hr glucose (adjusted for BMI, NSNPs=15)
35, fasting 
glucose (FG, adjusted for BMI, NSNPs=21) 
34, glycated haemoglobin (HbA1c, NSNPs=15)
36, fasting insulin (natural log 
transformed and adjusted for BMI, NSNPs=13)
34, fasting pro-insulin (adjusted for BMI and FG, NSNPs=10)
37, HOMA-B 
(NSNPs=15), HOMA-IR (NSNPs=15)
38 and insulin resistance 39. 
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Supplemental Table 11: MAGENTA Gene set enrichment results with FDR<0.05 
pheno DB Gene set 
EFF 
GS 






FLAGGED FLAGGED GENE NAMES 
CKDDN BIOCARTA Shh pathway 16 1.00E-05 0.0001 1 7 16 
DYRK1A, GLI1, GLI2, GLI3, GSK3B, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, 
PTCH1, SHH, SMO, DYRK1B, SUFU 
Combined DKD KEGG 
 
ascorbate and aldarate 
metabolism 17 9.00E-06 0.0001 1 7 22 
ALDH2, ALDH1B1, ALDH9A1, ALDH3A2, ALDH7A1, UGDH, UGT2B4, UGT2B7, UGT2B11, UGT2A1, 
UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, 
UGT1A3, MIOX, UGT2A3 
Combined DKD KEGG 
 pentose and 
glucuronate 
interconversions 20 3.00E-06 0.0002 1 8 24 
AKR1B1, GUSB, RPE, UGDH, UGP2, UGT2B4, UGT2B7, XYLB, UGT2B11, UGT2A1, DHDH, CRYL1, 
DCXR, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, 
UGT1A3, UGT2A3 
Combined DKD KEGG 
 porphyrin and 
chlorophyll metabolism 31 8.50E-05 0.0020 2 8 38 
ALAD, ALAS1, ALAS2, BLVRA, BLVRB, COX10, COX15, CP, CPOX, EPRS, FECH, FTH1, GUSB, HCCS, 
HMBS, HMOX1, HMOX2, PPOX, UGT2B4, UGT2B7, UROD, UROS, UGT2B11, UGT2A1, UGT2B28, 
UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, UGT2A3, 




PROCESS Hearing 27 1.00E-04 0.0020 1 8 29 
TIMM8A, DFNA5, COCH, MYO6, MYO7A, MYO7B, P2RX1, P2RX3, P2RX4, P2RX5, P2RX7, TCOF1, 
WFS1, ZFAND5, P2RX6, KCNQ4, ITM2B, WDR1, P2RX2, DFNB31, TIMM13, TIMM8B, MYO15A, 
CDHR5, CDH23, ESPN, OTOA, STRC, OC90 
Combined DKD KEGG 
drug metabolism other 
enzymes 39 3.00E-04 0.0102 2 8 48 
NAT1, NAT2, CDA, CES1, CYP2A6, CYP2A7, CYP3A7, CYP2A13, CYP3A4, CYP3A5, DPYD, DPYS, 
TYMP, GUSB, HPRT1, IMPDH1, IMPDH2, ITPA, TK1, TK2, TPMT, UGT2B4, UGT2B7, UCK2, UMPS, 
UPP1, XDH, CES2, GMPS, UGT2B11, UGT2A1, UPB1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, UCKL1, CYP3A43, UGT2A3, UCK1, 
UPP2, CES5A 
Combined DKD KEGG 
drug metabolism 
cytochrome p450 49 5.00E-04 0.0107 2 9 68 
ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7, ALDH3A1, ALDH1A3, ALDH3B1, ALDH3B2, 
AOX1, CYP1A2, CYP2A6, CYP2A7, CYP3A7, CYP2A13, CYP2B6, CYP2C19, CYP2C8, CYP2C9, 
CYP2C18, CYP2D6, CYP2E1, CYP3A4, CYP3A5, FMO1, FMO2, FMO3, FMO4, FMO5, GSTA1, 
GSTA2, GSTA3, GSTA4, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTP1, GSTT1, GSTZ1, MAOA, 
MAOB, MGST1, MGST2, MGST3, UGT2B4, UGT2B7, GSTO1, UGT2B11, UGT2A1, UGT2B28, 
UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, CYP3A43, 
UGT2A3, GSTO2, GSTA5, GSTK1 
Combined DKD KEGG 
metabolism of 
xenobiotics by 
cytochrome p450 47 5.00E-04 0.0125 2 9 66 
ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7, ALDH3A1, ALDH1A3, ALDH3B1, ALDH3B2, 
AKR1C4, CYP1A1, CYP1A2, CYP1B1, CYP3A7, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2C18, 
CYP2E1, CYP2F1, CYP3A4, CYP3A5, AKR1C1, AKR1C2, EPHX1, GSTA1, GSTA2, GSTA3, GSTA4, 
GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTP1, GSTT1, GSTZ1, MGST1, MGST2, MGST3, 
UGT2B4, UGT2B7, AKR1C3, GSTO1, UGT2B11, UGT2A1, DHDH, CYP2S1, UGT2B28, UGT1A10, 
UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, CYP3A43, UGT2A3, 
GSTO2, GSTA5, GSTK1 
Combined DKD KEGG retinol metabolism 45 1.80E-03 0.0212 2 8 61 
ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7, ALDH1A1, CYP1A1, CYP1A2, CYP2A6, 
CYP2A7, CYP3A7, CYP2A13, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2C18, CYP3A4, CYP3A5, 
CYP4A11, CYP26A1, RDH5, RPE65, UGT2B4, UGT2B7, PNPLA4, RDH16, DGAT1, ALDH1A2, LRAT, 
DHRS3, DHRS9, UGT2B11, DHRS4, UGT2A1, RDH8, RDH11, BCMO1, UGT2B28, UGT1A10, 
UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, RETSAT, CYP26B1, 
CYP3A43, UGT2A3, DGAT2, RDH12, RDH10, AWAT2, CYP4A22, DHRS4L2, CYP26C1 
Combined DKD REACTOME Glucuronidation 13 2.84E-04 0.0238 1 5 16 
UGDH, UGP2, UGT2B4, UGT2B7, UGT2B11, UGT2A1, SLC35D1, UGT2B28, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 
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pheno DB Gene set 
EFF 
GS 






FLAGGED FLAGGED GENE NAMES 
CKD Panther Cholesterol biosynthesis 10 8.00E-04 0.0252 1 4 11 FDFT1, FDPS, HMGCR, HMGCS1, HMGCS2, IDI1, MVD, MVK, PMVK, PDSS1, IDI2 
Combined DKD GOTERM 
Glucuronosyltransferase 
activity 15 1.00E-04 0.0304 1 6 20 
EXT1, EXT2, UGT2B4, UGT2B7, UGT2B11, UGT2A1, UGT2B28, UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3, CSGALNACT1, UGT2A3, UGT3A1, 
UGT3A2 
Combined DKD KEGG glutathione metabolism 40 3.20E-03 0.0350 2 7 49 
ANPEP, G6PD, GGT1, GGT7, GGT5, GCLC, GCLM, GPX1, GPX2, GPX3, GPX4, GPX5, GPX7, GSR, 
GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTP1, GSTT1, 
GSTZ1, IDH1, IDH2, MGST1, MGST2, MGST3, ODC1, PGD, RRM1, RRM2, SMS, SRM, GSTO1, 





And Beta 2 Adrenergic 
Receptor Pathway 12 2.50E-03 0.0366 1 4 12 
ADCY1, ADRB2, CFTR, GNAS, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, EZR, 
SLC9A3R1 
CKD+DKD BIOCARTA 
Attenuation of GPCR 
Signaling Pathway 13 3.50E-03 0.0384 1 4 13 
ARRB1, GNAS, GNB1, GNGT1, GRK4, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, 
PRKAR2B, PRKCA, PRKCB 
Combined DKD KEGG 
starch and sucrose 
metabolism 40 4.00E-03 0.0391 2 7 46 
AGL, AMY2A, AMY2B, G6PC, GAA, GANC, GBE1, GCK, GPI, GUSB, GYS1, GYS2, HK1, HK2, HK3, 
ENPP1, ENPP3, PGM1, PYGB, PYGL, PYGM, SI, UGDH, UGP2, UGT2B4, UGT2B7, MGAM, 
UGT2B11, UGT2A1, TREH, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, 
UGT1A4, UGT1A1, UGT1A3, PGM2, GBA3, G6PC2, UGT2A3, UXS1, PGM2L1 
CKD+DKD BIOCARTA 
Repression of Pain 
Sensation by the 
Transcriptional 
Regulator DREAM 14 3.60E-03 0.0394 1 4 14 
CREB1, CREM, FOS, JUN, OPRK1, POLR2A, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, 
PRKAR2B, MAPK3, KCNIP3 
CKD+DKD BIOCARTA 
Cytokines and 
Inflammatory Response 26 1.50E-03 0.0404 1 6 29 
CD4, CSF1, CSF2, CSF3, HLA-DRA, HLA-DRB1, IFNA1, IFNB1, IFNG, IL1A, IL2, IL3, IL4, IL5, IL6, IL7, 
IL8, IL10, IL11, IL12A, IL12B, IL13, IL15, LTA, PDGFA, TGFB1, TGFB2, TGFB3, TNF 
CKD+DKD REACTOME 
Cell extracellular matrix 
interactions 14 5.00E-04 0.0417 1 5 16 
ACTN1, FLNA, FLNC, ILK, ITGB1, LIMS1, PXN, RSU1, TESK1, VASP, ARHGEF6, FERMT2, PARVB, 
FBLIM1, LIMS2, PARVA 
Combined DKD Panther FAS signaling pathway 22 1.10E-03 0.0424 1 6 22 
PARP1, PARP4, CAPG, CASP6, CASP7, CASP8, CASP10, CYC1, DFFB, GSN, LMNA, LMNB1, CFLAR, 
PARP2, PARP3, NOD1, FAF1, NLRP1, LMNB2, SCIN, IFLTD1, NLRP10 
CKD+DKD BIOCARTA 
Phospholipase C-epsilon 
pathway 12 2.10E-03 0.0426 1 4 12 
ADCY1, ADRB2, GNAS, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, PTGER1, 
RAP2B, PLCE1 
Combined DKD KEGG 
steroid hormone 
biosynthesis 41 4.70E-03 0.0480 2 7 52 
STS, AKR1C4, COMT, CYP1A1, CYP1B1, CYP3A7, CYP3A4, CYP3A5, CYP7A1, CYP11A1, CYP11B1, 
CYP11B2, CYP17A1, CYP19A1, CYP21A2, AKR1C1, AKR1C2, HSD3B1, HSD3B2, HSD11B1, 
HSD11B2, HSD17B1, HSD17B3, HSD17B2, SRD5A1, SRD5A2, AKR1D1, SULT1E1, SULT2B1, 
UGT2B4, UGT2B7, HSD17B8, HSD17B6, AKR1C3, CYP7B1, UGT2B11, UGT2A1, HSD17B12, 
HSD17B7, UGT2B28, UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, 
UGT1A1, UGT1A3, CYP3A43, SRD5A3, UGT2A3 
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Supplemental Table 12: Characteristics of the patients selected for the whole exome sequencing 
  FinnDiane Steno SDR 
Group 
Controls (no 














(56) 46 (54) 74 (42) 139 (57) 49 (78) 130 (49) 62 (61) 








59) 55±13 (33-84) 52±12 (29-84) 
Age at Onset ± sd (yr) 13±7 13±7 13±7 15±7 15±10 (0-32) 16±9 (1-35) 13±8 (1-33) 15±8 (0-31) 15±9 (0-35) 14±8 (1-35) 
Duration ± sd (yr) 43 ± 7 43 ± 6 34 ± 7 30 ± 7 38±8 39±6 - - 40±10 38±11 
  (32-66) (33-56) - - (30-63) (30-53) - - (27-74) (13-66) 
Time to maA ± sd (yr) - - 16 ± 3 - - - 18±3 - - 29±11 
(range) - - (8-20) - -   (12-25) - - (11-64) 
Time to ESRD ± sd (yr) - - - 20 ± 3 - - - 26±5 - - 
(range) - - - (15-27) -   - (18-24) - - 
Time to RT/ laser ± sd (yr) - 26 ± 8 17 ± 5 16 ± 5 - 28±7 19±5 16±4 - - 
(range) - (12-47) (8-33) (2-33) - (12-41) (8-35) (6-27) - - 








1.5 8.4±1.0 8.7±1.2 9.5±1.4 9.8±1.5 7.0±0.9 8.1±1.2 
Further definitions             
all cases had proliferative 
RT 




patients who did 
not have DN 
61/62 cases had 
proliferative RT 
RT: diabetic retinopathy, based on either a clinical diagnosis or laser treatment  
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Supplemental Table 13. Top 20 results of single variant analysis for WES ‘ESRD vs. no DKD’ using the score test 
Chr:pos Id Maf Pval Ref/alt Ctrlcnt Casecnt Gene type 
1:224492543 rs188427269 0.0023184 3.3046e-07 G/T 482/0/0 166/3/0 NVL INTRON 
2:212243703 rs13003941 0.3524 3.5931e-06 G/T 182/229/71 92/67/10 ERBB4 UTR_3_PRIME 
9:37729786 rs1359590 0.20015 4.8522e-06 C/T 277/189/16 132/35/2 FRMPD1 NON_SYNONYMOUS_CODING 
21:34697316 rs112371220 0.0054687 5.4552e-06 C/T 474/1/0 164/4/1 IFNAR1 UTR_5_PRIME 
19:1782842 rs146522765 0.003864 7.4797e-06 G/T 482/0/0 164/5/0 ATP8B3 EXON 
7:27168590 rs1801085 0.10974 1.2659e-05 A/G 402/77/3 113/52/4 HOXA4 UPSTREAM 
7:27159136 rs6969780 0.11283 1.4914e-05 G/C 399/80/3 113/51/5 HOXA3 INTRON 
2:43518932 2:43518932 0.0092736 1.7014e-05 AC/A 479/3/0 160/9/0 THADA INTRON 
2:43804334 rs149038509 0.0092736 1.7014e-05 C/T 479/3/0 160/9/0 THADA EXON 
19:4502778 19:4502778 0.0030912 1.7702e-05 G/A 482/0/0 165/4/0 PLIN4 DOWNSTREAM 
2:212251864 rs3748962 0.3408 2.0785e-05 T/C 192/222/68 94/65/10 ERBB4 SYNONYMOUS_CODING 
5:157078632 rs13181859 0.0015528 2.9199e-05 G/A 479/0/0 167/2/0 SOX30 NON_SYNONYMOUS_CODING 
1:64015722 rs41285382 0.0092736 2.9641e-05 T/C 480/2/0 159/10/0 DLEU2L EXON 
12:62996508 12:62996508 0.0015576 3.1046e-05 G/A 477/0/0 167/2/0 C12orf61 UPSTREAM 
5:132086671 rs111822821 0.0015456 3.2297e-05 G/A 482/0/0 167/2/0 SEPT8 SYNONYMOUS_CODING 
12:53468971 rs142430651 0.0015456 3.2926e-05 G/C 482/0/0 167/2/0 SPRYD3 SYNONYMOUS_CODING 
8:107531123 8:107531123 0.0015456 3.5069e-05 G/T 482/0/0 167/2/0 OXR1 INTRON 
X:12908121 rs192357402 0.0015456 3.5163e-05 C/T 482/0/0 167/2/0 . . 
3:188595287 rs182465976 0.0015456 3.7313e-05 A/G 482/0/0 167/2/0 LPP UTR_3_PRIME 
7:27146202 rs61384251 0.12133 3.8108e-05 A/G 390/88/4 111/54/4 HOXA3 UPSTREAM 
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Supplemental Table 14. Top 20 associations for WES ‘Late DKD’ using the single variant score test 
Chr:pos Id Maf Pval Ref/alt Casecnt Ctrlcnt Gene type 
15:75762082 rs117245151 0.011992 4.0048e-05 G/A 458/21/0 478/2/0 PTPN9 INTRON 
7:27168590 rs1801085 0.1147 5.3839e-05 A/G 400/76/3 352/118/10 HOXA4 UPSTREAM 
1:35562965 rs2971408 0.10323 6.0045e-05 G/A 2/70/407 5/114/361 ZMYM1 NON_SYNONYMOUS_CODING 
7:27159136 rs6969780 0.11731 7.3659e-05 G/C 397/79/3 351/118/11 HOXA3 INTRON 
1:1222958 rs111819661 0.015328 7.7877e-05 C/T 450/25/0 467/4/0 SCNN1D DOWNSTREAM 
6:126334041 rs2206941 0.29406 8.2189e-05 G/A 28/187/264 57/207/216 TRMT11 INTRON 
7:137561465 rs77218976 0.03806 9.2539e-05 G/A 427/52/0 459/21/0 CREB3L2 UTR_3_PRIME 
1:1195690 rs11260568 0.013034 0.0001173 G/C 457/22/0 477/3/0 LOC100128842 INTRON 
1:1196374 rs72894077 0.013034 0.0001173 C/T 457/22/0 477/3/0 LOC100128842 INTRON 
6:126299264 rs9388464 0.29249 0.00013887 A/T 28/187/264 57/204/219 HINT3 UTR_3_PRIME 
6:126288023 rs3757212 0.29041 0.00013905 T/C 26/189/264 57/202/221 HINT3 INTRON 
11:10650350 rs190761149 0.0067779 0.00014425 G/A 466/13/0 480/0/0 MRVI1 SYNONYMOUS_CODING 
6:126300270 rs6909664 0.29145 0.0001443 G/A 27/188/264 57/203/220 HINT3 UTR_3_PRIME 
19:4945974 rs2250978 0.039749 0.00015331 T/C 2/50/426 0/22/456 UHRF1 SYNONYMOUS_CODING 
12:70914045 rs5798988 0.028676 0.00015412 A/AAAGT 438/41/0 466/14/0 PTPRB UTR_3_PRIME 
15:37109504 rs17417429 0.10949 0.00015916 G/C 358/110/11 409/64/7 CSNK1A1P INTRON 
6:126299984 rs10659948 0.29197 0.00016327 A/ACT 27/189/263 56/205/219 HINT3 UTR_3_PRIME 
2:223783841 rs13000358 0.051616 0.00016344 G/A 414/60/5 453/25/2 ACSL3 SYNONYMOUS_CODING 
2:212243703 rs13003941 0.34619 0.00017464 G/T 180/228/71 229/208/43 ERBB4 UTR_3_PRIME 
2:71413771 rs357781 0.20177 0.0001777 G/C 330/136/13 278/179/23 PAIP2B UTR_3_PRIME 
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Supplemental Table 15: Top 10 associations to WES ‘Late DKD’ with VT with 4 masks 
Position n.pass.v P-value Gene 
PTV+missense    
11:68673615-68707139 17 4.9e-05 IGHMBP2 
13:53035097-53049198 8 0.00012 CKAP2 
20:57415627-57430300 13 0.00012 GNAS 
3:123213786-123286612 3 0.00014 PTPLB 
14:24837601-24846073 12 0.00025 NFATC4 
10:45798933-45803264 5 0.00036 OR13A1 
20:1099459-1146882 9 0.00049 PSMF1 
19:36509815-36518135 5 0.0005 CLIP3 
11:35454383-35515695 14 0.00056 PAMR1 
15:59750819-59813476 8 0.00063 FAM81A 
PTV+broad    
22:38013000-38028693 5 3.1e-05 GGA1 
11:68673615-68707139 9 0.00012 IGHMBP2 
19:12954416-12984677 7 0.00028 MAST1 
11:102094424-102101456 2 0.00029 YAP1 
20:1099459-1146882 8 0.00049 PSMF1 
13:28794420-28866586 6 0.00059 PAN3 
17:38933291-38938348 5 0.00062 KRT27 
14:24837601-24846073 9 0.00063 NFATC4 
5:110835655-110835762 2 0.00066 STARD4 
18:77891038-77896253 6 0.00067 ADNP2 
PTV+strict    
19:6743822-6744853 2 0.00021 TRIP10 
10:49931476-50018711 2 0.0006 WDFY4 
19:19166642-19168396 2 0.00062 ARMC6 
5:133686100-133702055 3 0.00072 CDKL3 
11:128781680-128781799 2 0.00087 KCNJ5 
19:33370070-33450911 4 0.00089 CCDC123 
2:163124596-163144807 7 0.00103 IFIH1 
11:76157998-76170978 2 0.00113 C11orf30 
1:151734628-151734961 2 0.0012 MRPL9 
3:54952509-54952627 2 0.0012 LRTM1 
PTV+only    
11:67815031-67818400 2 0.00088 TCIRG1 
3:54952509-54952627 2 0.00113 LRTM1 
10:49931476-50018711 2 0.0012 WDFY4 
2:163124596-163144807 7 0.0015 IFIH1 
17:8701157-8701167 2 0.0016 MFSD6L 
2:43458439-43804337 3 0.0022 THADA 
19:15233517-15235879 2 0.0025 ILVBL 
6:101079090-101248282 2 0.0027 ASCC3 
5:149676827-149677481 2 0.0028 ARSI 
14:50117073-50141063 2 0.003 POLE2 
N.pass.v = number of variants passing the mask definitions 
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Supplemental Table 16: Top 10 associations to WES ‘Late DKD’ using SKAT-O with 4 different masks. 
Position n.pass.v n.sing.v P-value Gene 
PTV+missense  
13:53035097-53049198 8 4 0.00012156 CKAP2 
10:45798933-45803264 5 4 0.00048573 OR13A1 
3:54952509-54959089 5 2 0.00063959 LRTM1 
1:151139478-151140817 6 3 0.0006738 SCNM1 
20:57415627-57430300 13 9 0.00086146 GNAS 
7:18066456-18067243 5 3 0.0012014 PRPS1L1 
19:6730150-6736607 19 8 0.0012488 GPR108 
17:38933291-38938348 6 2 0.0012682 KRT27 
19:42392130-42410847 17 8 0.0013578 ARHGEF1 
3:122103120-122128670 3 1 0.0015433 FAM162A 
PTV+broad     
11:68673615-68707139 9 6 0.00024156 IGHMBP2 
13:53035097-53049198 7 4 0.0004632 CKAP2 
7:18066456-18067059 4 3 0.00054833 PRPS1L1 
3:54952509-54952627 2 0 0.00064301 LRTM1 
10:45799065-45799733 2 1 0.00076937 OR13A1 
18:77891038-77896253 6 3 0.0011557 ADNP2 
13:28794420-28866586 6 3 0.0011976 PAN3 
17:38933291-38938348 5 2 0.0013916 KRT27 
5:37815803-37816112 3 1 0.0014264 GDNF 
3:122103120-122128670 3 1 0.0015433 FAM162A 
PTV+strict     
3:54952509-54952627 2 0 0.00064301 LRTM1 
3:150384657-150421396 4 2 0.00066435 FAM194A 
3:39228815-39229781 3 2 0.0035418 XIRP1 
6:45909349-45916999 2 0 0.0035639 CLIC5 
9:75774283-75777764 2 1 0.0072129 ANXA1 
1:151773808-151774922 4 2 0.0076929 LINGO4 
17:8701157-8701167 2 1 0.0088381 MFSD6L 
17:40933276-40948304 4 3 0.0089785 WNK4 
1:46016829-46034879 3 1 0.0094446 AKR1A1 
3:38307398-38318485 2 1 0.0094456 SLC22A13 
PTV+only     
3:54952509-54952627 2 0 0.00064301 LRTM1 
19:15233517-15235879 2 1 0.0016954 ILVBL 
17:8701157-8701167 2 1 0.0088381 MFSD6L 
3:38307398-38318485 2 1 0.0094456 SLC22A13 
2:43458439-43804337 3 2 0.010444 THADA 
16:334920-336888 5 1 0.010482 PDIA2 
17:5486023-5487821 2 1 0.01087 NLRP1 
22:41257273-41257834 3 2 0.01437 DNAJB7 
22:19189003-19220052 2 1 0.017846 CLTCL1 
5:111500816-111519735 2 1 0.018258 EPB41L4A 
N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants 
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Supplemental Table 17: Top 10 associations to WES ‘Late DKD’ using SKAT with 4 masks 
Position n.pass.v n.sing.v P-value Gene 
PTV+missense 
13:53035097-53049198 8 4 0.00041305 CKAP2 
3:54952509-54959089 5 2 0.00060623 LRTM1 
10:45798933-45803264 5 4 0.00072656 OR13A1 
7:18066456-18067243 5 3 0.00091793 PRPS1L1 
1:151139478-151140817 6 3 0.0011152 SCNM1 
5:37815803-37816112 5 3 0.0013631 GDNF 
8:70585265-70744856 14 6 0.0018813 SLCO5A1 
14:75321989-75330435 10 4 0.0022685 PROX2 
7:1855776-2269648 13 9 0.0026609 MAD1L1 
18:42260994-42643270 16 12 0.0028434 SETBP1 
PTV+broad     
13:53035097-53049198 7 4 0.00056746 CKAP2 
3:54952509-54952627 2 0 0.00059024 LRTM1 
10:45799065-45799733 2 1 0.00072803 OR13A1 
7:18066456-18067059 4 3 0.0010284 PRPS1L1 
5:37815803-37816112 3 1 0.0013592 GDNF 
18:42281357-42618578 13 10 0.0023793 SETBP1 
7:1937887-2269648 11 8 0.0024099 MAD1L1 
6:45882076-45922972 7 2 0.0029219 CLIC5 
1:186862169-186946869 3 2 0.0030571 PLA2G4A 
3:150377770-150421666 10 6 0.0031755 FAM194A 
PTV+strict     
3:150384657-150421396 4 2 0.00057312 FAM194A 
3:54952509-54952627 2 0 0.00059024 LRTM1 
6:45909349-45916999 2 0 0.0025361 CLIC5 
1:46016829-46034879 3 1 0.0062285 AKR1A1 
9:75774283-75777764 2 1 0.0062769 ANXA1 
17:40933276-40948304 4 3 0.0069954 WNK4 
17:34861135-34881073 3 2 0.0076076 MYO19 
3:121491422-121544920 5 3 0.0081831 IQCB1 
3:39228815-39229781 3 2 0.0098747 XIRP1 
19:15233517-15235879 4 1 0.010502 ILVBL 
PTV+only     
3:54952509-54952627 2 0 0.00059024 LRTM1 
19:15233517-15235879 2 1 0.0024413 ILVBL 
16:334920-336888 5 1 0.0067681 PDIA2 
3:38307398-38318485 2 1 0.013673 SLC22A13 
17:8701157-8701167 2 1 0.015528 MFSD6L 
17:5486023-5487821 2 1 0.018495 NLRP1 
17:72363857-72366663 2 1 0.021549 GPR142 
14:24566139-24569423 5 4 0.024283 PCK2 
22:19189003-19220052 2 1 0.024653 CLTCL1 
3:149238595-149245675 1 0 0.024785 WWTR1 
N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants 
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Supplemental table 18: Top 10 associations to WES ‘ESRD vs. no DKD’ with VT and 4 masks 
Position n.pass.v P-value Gene 
PTV+missense    
12:518580-550003 7 2.1e-05 CCDC77 
16:28877711-28884952 7 3.1e-05 SH2B1 
12:102108407-102120196 4 8.6e-05 CHPT1 
14:23846482-23848306 3 0.00012 CMTM5 
11:5775980-5776749 5 0.00019 OR52N4 
12:100685365-100732822 8 0.00032 SCYL2 
15:44065537-44068996 7 0.00035 ELL3 
9:130494915-130496639 6 0.00037 TOR2A 
20:61907925-61919795 12 0.00053 ARFGAP1 
1:156182876-156209351 6 0.0006 PMF1 
PTV+broad    
12:102113935-102120196 3 3.4e-05 CHPT1 
6:31525437-31526261 3 0.000124 NFKBIL1 
14:23846482-23848306 3 0.00015 CMTM5 
13:28794420-28866586 6 0.00018 PAN3 
16:28877939-28884858 5 0.00029 SH2B1 
6:160543080-160577058 9 0.00054 SLC22A1 
1:229730547-229738417 4 0.00073 TAF5L 
1:228612639-228612822 3 0.00077 HIST3H3 
14:52472205-52534758 18 0.0008 NID2 
11:5775984-5776749 4 0.00104 OR52N4 
PTV+strict    
8:22884744-22885843 2 0.00019 TNFRSF10B 
17:77100210-77102746 2 0.0006 HRNBP3 
8:133083602-133090167 2 0.00083 HHLA1 
6:136560616-136560647 2 0.00114 FAM54A 
4:38798235-38800282 5 0.0012 TLR1 
19:8138170-8203184 3 0.0016 FBN3 
17:72954475-72960618 2 0.0017 C17orf28 
18:21752415-21957382 3 0.0018 OSBPL1A 
6:34003851-34100981 4 0.0018 GRM4 
8:38834236-38845519 3 0.0025 HTRA4 
PTV-only    
8:22884744-22885843 2 0.00017 TNFRSF10B 
8:133083602-133090167 2 0.00072 HHLA1 
19:8138170-8203184 3 0.0012 FBN3 
3:4355014-4355131 2 0.0025 SETMAR 
11:121008192-121058691 3 0.0035 TECTA 
4:47538723-47574170 2 0.0035 ATP10D 
10:75184515-75187483 2 0.0041 ZMYND17 
3:9960192-9974543 3 0.0049 IL17RC 
2:169727989-169728004 2 0.0056 SPC25 
22:42473722-42473986 3 0.0061 FAM109B 
N.pass.v = number of variants passing the mask definitions 
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Supplemental Table 19: Top 10 associations to WES ‘ESRD vs. no DKD’ with SKAT-O with 4 masks 
Position n.pass.v n.sing.v P-value Gene 
PTV+missense  
11:5775980-5776749 4 3 2.8913e-05 OR52N4 
12:102108407-102120196 3 1 4.3482e-05 CHPT1 
14:23846482-23848306 2 2 8.5563e-05 CMTM5 
12:100685365-100732822 6 2 8.6197e-05 SCYL2 
12:518580-550003 7 4 9.0216e-05 CCDC77 
2:43458176-43819161 21 12 0.00015065 THADA 
11:62575105-62598496 5 3 0.00016229 STX5 
15:44065537-44068996 3 2 0.00016763 ELL3 
20:61907925-61919795 9 4 0.00027894 ARFGAP1 
13:28794420-28866586 7 5 0.00030024 PAN3 
PTV+broad     
12:102113935-102120196 2 0 1.8982e-05 CHPT1 
13:28794420-28866586 5 3 2.0813e-05 PAN3 
6:31525437-31526261 2 2 8.4194e-05 NFKBIL1 
14:23846482-23848306 2 2 8.5563e-05 CMTM5 
11:5775984-5776749 3 2 0.00017668 OR52N4 
11:62592777-62598496 3 1 0.00021827 STX5 
20:44047493-44054249 8 7 0.0002694 PIGT 
5:39376125-39394413 3 1 0.00029884 DAB2 
17:7094043-7107367 5 4 0.00049654 DLG4 
19:49407625-49424482 8 6 0.00054261 NUCB1 
PTV+strict     
8:22884744-22885843 2 2 9.8064e-05 TNFRSF10B 
4:38798235-38800282 4 3 0.00046089 TLR1 
17:77100210-77102746 1 0 0.00062522 HRNBP3 
19:10738409-10748401 3 2 0.0010388 SLC44A2 
16:61687916-61689548 1 0 0.0012592 CDH8 
4:186111299-186111306 2 1 0.0013119 KIAA1430 
8:133083602-133090167 2 2 0.0013399 HHLA1 
8:38834236-38845519 2 1 0.0013474 HTRA4 
16:89985750-89986215 2 1 0.0014125 MC1R 
17:41004777-41006634 2 1 0.0014339 AOC3 
PTV+only     
8:22884744-22885843 2 2 9.8064e-05 TNFRSF10B 
8:133083602-133090167 2 2 0.0013399 HHLA1 
16:89985750-89986215 2 1 0.0014125 MC1R 
11:67786064-67789293 2 0 0.0020716 ALDH3B1 
3:4355014-4355131 2 2 0.0020738 SETMAR 
19:8138170-8203184 1 1 0.0028026 FBN3 
4:47538723-47574170 1 1 0.0032767 ATP10D 
22:41257273-41257834 3 2 0.0033414 DNAJB7 
11:121008192-121058691 2 2 0.0033577 TECTA 
1:151493123-151508777 1 1 0.0037668 CGN 
N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants 
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Supplemental Table 20: Top 10 associations to WES ‘ESRD vs. no DKD’ with SKAT with 4 masks 
Position n.pass.v n.sing.v P-value Gene 
PTV+missense 
2:43458176-43819161 21 12 8.3459e-05 THADA 
5:39376125-39394413 8 2 0.00018914 DAB2 
17:34071959-34079805 9 5 0.00020671 GAS2L2 
12:102108407-102120196 3 1 0.00021871 CHPT1 
14:23846482-23848306 2 2 0.00026538 CMTM5 
11:62575105-62598496 5 3 0.00038847 STX5 
12:57345928-57351029 3 2 0.00055704 RDH16 
5:63986481-64013795 5 3 0.00066429 FAM159B 
5:157053392-157078632 7 5 0.00088391 SOX30 
4:186111299-186112220 4 3 0.0010538 KIAA1430 
PTV+broad     
12:102113935-102120196 2 0 0.00021073 CHPT1 
5:39376125-39394413 3 1 0.00022996 DAB2 
6:31525437-31526261 2 2 0.00025304 NFKBIL1 
14:23846482-23848306 2 2 0.00026538 CMTM5 
11:62592777-62598496 3 1 0.00049172 STX5 
5:63986481-63991426 4 2 0.00061686 FAM159B 
17:7094043-7107367 5 4 0.00086232 DLG4 
5:157053392-157078632 7 5 0.00088391 SOX30 
17:77100210-77111580 2 1 0.0010418 HRNBP3 
22:21235389-21242054 1 0 0.0010726 SNAP29 
PTV+strict     
8:22884744-22885843 2 2 0.0002888 TNFRSF10B 
17:77100210-77102746 1 0 0.00062522 HRNBP3 
19:10738409-10748401 3 2 0.00089608 SLC44A2 
16:89985750-89986215 2 1 0.001117 MC1R 
17:41004777-41006634 2 1 0.0011256 AOC3 
4:186111299-186111306 2 1 0.0012193 KIAA1430 
11:67786064-67789293 2 0 0.001238 ALDH3B1 
16:61687916-61689548 1 0 0.0012592 CDH8 
1:104116940-104117921 2 0 0.0022375 AMY2B 
19:8138170-8203184 1 1 0.0028026 FBN3 
PTV+only     
8:22884744-22885843 2 2 0.0002888 TNFRSF10B 
16:89985750-89986215 2 1 0.001117 MC1R 
11:67786064-67789293 2 0 0.001238 ALDH3B1 
19:8138170-8203184 1 1 0.0028026 FBN3 
4:47538723-47574170 1 1 0.0032767 ATP10D 
12:55863064-55863661 3 1 0.0034269 OR6C70 
1:151493123-151508777 1 1 0.0037668 CGN 
2:169727989-169728004 1 1 0.0037668 SPC25 
13:40235019-40261900 1 1 0.0042598 COG6 
16:10837724-10846536 1 1 0.0042598 NUBP1 
N.pass.v = number of variants passing the mask definitions; N.sing.v = number of singleton variants 
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Supplemental Table 21: Gene-sets which showed enrichment in WES association data on the ‘Late DKD’ phenotype, with permutation 
(N=100) results 
    
Real data 
 Random data 
(# of times a better finding is observed in 






SKATO mask NES Pval** FDR FWER 
 
NES Pval FDR FWER NES & FDR 
FUNC_meta_T1D-ESRDvsNonESRD_emmax_FD-SDR-ED1 









0.04 0.1 0.08 0.09 0.03 
TOP_meta_T1D-macro-ESRD_emmax_FD-SDR-Cam-ED1 





0 0 0.02 0.02 0 
              
Non-significant, tested gene sets              
Gene set Genes             
Orpha.kidney 466             
GWAS.kidney 65             
GO.BP.kidney 357             
MGI.kidney 836             
expression.kidney 1597             
LitMS.kidney 1349             
overexpressed.in.isolated.mouse.podocytes 756             
mouse.K.O.has.abnormal.podocyte 39             
causes.rare.human.glomerular.disease 45             
TOP_meta_T1D-CKD_emmax_FD-SDR-ED1 67             
TOP_meta_T1D-CKDDN_emmax_FD-SDR-ED1 69             
TOP_meta_T1D-ESRD_emmax_FD-SDR-ED1 243             
TOP_meta_T1D-ESRDvsNonESRD_emmax_FD-SDR-ED1 56             
TOP_meta_T1D-micro_emmax_FD-SDR-Cam-ED1 22             
TOP_Meta_T1D-T2D_CKDDN_min_emmax_131202 93             





   
 
     
TOP_Meta_T1D-T2D_MACROESRD_min_emmax_131101 181             
TOP_Meta_T1D-T2D_MICRO_min_emmax_131101 35             
TOP_Meta_T2D_CKD_min_emmax_131202 4             
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TOP_Meta_T2D_DN_min_emmax_131101 6             
TOP_Meta_T2D_eGFR_min_emmax_131128 26             
TOP_Meta_T2D_ESRDvsALL_min_emmax_131128 186             
FUNC_meta_T1D-CKD_emmax_FD-SDR-ED1 13             
FUNC_meta_T1D-CKDDN_emmax_FD-SDR-ED1 6             
FUNC_meta_T1D-DN_emmax_FD-SDR-Cam-ED1 1             
FUNC_meta_T1D-ESRD_emmax_FD-SDR-ED1 30             
FUNC_meta_T1D-macro-ESRD_emmax_FD-SDR-Cam-ED1 4             
FUNC_Meta_T1D-T2D_CKD_min_emmax_131202 3             
FUNC_Meta_T1D-T2D_CKDDN_min_emmax_131202 12             
FUNC_Meta_T1D-T2D_MACROESRD_min_emmax_131101 23             
FUNC_Meta_T2D_eGFR_min_emmax_131128 14             
FUNC_Meta_T2D_MACROESRD_min_emmax_131101 6             
FUNC_Meta_T2D_MICRO_min_emmax_131101 2             
Podo_Axonal Guidance Signaling 159             
Podo_Signaling by Rho Family GTPases 97             
Podo_Epithelial Adherens Junction Signaling 66             
Podo_ILK Signaling 79             
Podo_RhoA Signaling 57             
Podo_Integrin Signaling 79             
Podo_Germ Cell-Sertoli Cell Junction Signaling 65             
*NES= Normalised Enrichment Score 
**In the GSEA report, a p value of zero (0.0) indicates an actual p value of less than 1/number-of-permutations. For example, if the analysis performed 100 
permutations, a reported p value of 0.0 indicates an actual p value of less than 0.001. For a more accurate p-value, increase the number of permutations 
performed by the analysis.  
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Supplemental Table 22: ABACUS association analysis results for the top SNPs from the GWAS discovery 
Pheno Cohort SNP CHR P value Gene 
CKD FINNDIANE rs1622208 1 4.80E-06 MAST2 
CKD FINNDIANE rs6682683 1 4.51E-06 MAST2 
ESRD vs. NO DKD FINNDIANE rs17024167 1 7.97E-07 PHGDH 
CKD EURODIAB rs13384229 2 3.16E-06 ALS2 
CKD+ DKD EURODIAB rs11898503 2 4.31E-06 KLHL29 
DKD & Late DKD EURODIAB rs906651 2 4.51E-06 LRP1B 
CKD+DKD FINNDIANE rs7577925 2 7.97E-07 NCKAP5 
Late DKD FINNDIANE rs3773786 3 3.77E-07 IQCJ-SCHIP1 
Late DKD & CKD+DKD FINNDIANE rs6785153 3 3.77E-07 IQCJ-SCHIP1 
Combined DKD FINNDIANE rs1061860 3 7.97E-07 MB21D2 
Combined DKD FINNDIANE rs2986 3 7.97E-07 MB21D2 
Late DKD FINNDIANE rs1434546 4 4.03E-06 BMPR1B 
Late DKD FINNDIANE rs1545326 4 4.27E-06 BMPR1B 
Late DKD FINNDIANE rs17022885 4 4.31E-06 BMPR1B 
CKD FINNDIANE rs4352548 4 6.35E-07 BTC 
CKD FINNDIANE rs3796588 4 6.34E-07 GUCY1A3 
Late DKD FINNDIANE rs10037055 5 1.73E-06 NSD1 
Late DKD FINNDIANE rs2244012 5 4.00E-06 RAD50 
Early DKD SDR rs1970549 6 4.77E-06 KCNQ5 
Early DKD EURODIAB rs1019046 7 1.64E-06 GLI3 
CKD SDR rs7778308 7 3.65E-06 GRM8 
ESRD vs. NO DKD FINNDIANE rs6983307 8 1.09E-06 ST18 
Late DKD & CKD+DKD & ESRD vs. NO DKD FINNDIANE rs10121901 9 1.89E-06 ABCA1 
Late DKD & CKD+DKD & ESRD vs. NO DKD FINNDIANE rs2066720 9 1.96E-06 ABCA1 
CKD FINNDIANE rs2855171 9 4.37E-06 ABL1 
Late DKD SDR rs10794197 10 4.66E-06 CTBP2 
Early DKD NFS-ORPS rs2236418 10 1.73E-06 GAD2 
Early DKD NFS-ORPS rs10508715 10 1.73E-06 MYO3A 
Early DKD NFS-ORPS rs994502 10 1.73E-06 MYO3A 
CKD FINNDIANE rs1784175 11 4.39E-06 OPCML 
Late DKD & Combined DKD FINNDIANE rs3059 11 1.73E-06 POLR2L 
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Pheno Cohort SNP CHR P value Gene 
Late DKD FINNDIANE rs3741935 12 1.80E-06 PRMT8 
Combined DKD EURODIAB rs9540711 13 4.03E-06 PCDH9 
Late DKD FINNDIANE rs2278709 15 2.15E-06 ARNT2 
Early DKD SDR rs678892 15 3.53E-06 PIGB 
Late DKD FINNDIANE rs173839 16 3.65E-06 CDH13 
ESRD vs. NO DKD EURODIAB rs4782574 16 2.89E-06 OSGIN1 
Late DKD FINNDIANE rs8075035 17 2.15E-06 AIPL1 
CKD+DKD SDR rs1972933 17 1.28E-06 MAP2K6 
Early DKD NFS-ORPS rs7234763 18 7.18E-07 PTPRM 
Late DKD FINNDIANE rs2544795 19 3.20E-06 SULT2B1 
Late DKD FINNDIANE rs2665579 19 2.74E-06 SULT2B1 
ESRD vs. NO DKD EURODIAB rs17420378 20 6.34E-07 STK4 
ESRD vs. NO DKD EURODIAB rs6073622 20 6.34E-07 STK4 
ESRD vs. NO DKD EURODIAB rs7266289 20 6.34E-07 STK4 
ESRD vs. NO DKD EURODIAB rs7271519 20 6.34E-07 STK4 
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Supplemental Table 23: ABACUS association analysis results for the top SNPs from the WES discovery 
Pheno Cohort SNP CHR P value Gene 
ESRD vs. no DKD FINNDIANE rs2297955_G_A 1 1.66E-06 ACTN2 
ESRD vs. no DKD FINNDIANE rs41293273_C_T 1 1.14E-07 NSUN4 
ESRD vs. no DKD FINNDIANE rs41293275_T_A 1 3.41E-07 NSUN4 
Late DKD STENO rs2289239_A_G 2 4.09E-06 POLR1A 
Late DKD SDR rs6775309_T_C 3 2.15E-06 GPD1L 
Late DKD SDR rs6788436_C_T 3 2.15E-06 GPD1L 
Late DKD SDR rs6799559_G_A 3 2.15E-06 GPD1L 
Late DKD SDR rs6799728_T_A 3 2.15E-06 GPD1L 
Late DKD SDR rs2813_C_T 3 3.08E-06 GPD1L 
ESRD vs. no DKD STENO rs55642964_C_T 4 1.82E-06 SH3TC1 
ESRD vs. no DKD STENO rs2136662_G_T 16 9.10E-07 OSGIN1 
ESRD vs. no DKD STENO rs3087852_A_G 17 8.89E-07 PSMD3 
ESRD vs. no DKD STENO rs12102_A_G 18 2.05E-06 SERPINB2 
ESRD vs. no DKD STENO rs3217292_G_GTGAGA 18 2.05E-06 SERPINB2 
ESRD vs. no DKD STENO rs6093_T_C 18 2.05E-06 SERPINB2 
ESRD vs. no DKD STENO rs6095_G_C 18 2.05E-06 SERPINB2 
ESRD vs. no DKD STENO rs6098_G_A 18 2.05E-06 SERPINB2 
ESRD vs. no DKD STENO var_chr18_61569819_T_TTTAAGTTTCTGGGGC 18 2.05E-06 SERPINB2 
ESRD vs. no DKD FINNDIANE rs2295490_G_A 20 4.64E-06 TRIB3 
Late DKD FINNDIANE rs2073278_A_G 22 2.65E-06 SBF1 
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Supplemental Table 24: DAVID functional clustering of the genes mapped by the SNPs selected by the ABACUS software on GWAS data 
Key Terms Genes Score 





kidney & urogenital system development, positive 
regulation of developmental process 
AGTR1,APC,GLI3,GNAS,HELLS,IL7R,NTN1,ROBO1,SART1,SLIT2,TGFBR2 2.76 







hemopoietic or lymphoid organ development, 




positive regulation of kinase activity, positive regulation 




cellular response to stress, regulation of apoptosis ABL1,APC,BIRC5,BRCA2,CASP9,CD40LG,CHST11,FOXN3,GLI3,HELLS,KRAS,M
AP2K6,NUAK2,PAK7,RPA3,RPS3,SART1,SCAP,STK4,TNFRSF8,YWHAB 
1.91 
actin cytoskeleton organization ABL1,APC,ATG4A,BIRC5,BRCA2,CNTROB,DIAPH2,KRAS,LIMA1,MYH6,MYH9,
MYO3A,NCK2,NUAK2 
1.77 
lipid moiety-binding region:S-palmitoyl cysteine, 
lipoprotein, palmitate 
ABL1,AGTR1,GAD2,GAP43,GNAS,KRAS,LRP1B,RGS7,SYT1 1.70 







inflammatory response, Toll-Interleukin receptor, 




leukocyte proliferation/activation, lymphocyte 
proliferation, mononuclear cell proliferation 
APC,BLNK,CD40LG,HELLS,IL7R,KIF13B,MYH9,NCK2 1.54 
SH2 domain ABL1,BLNK,CBL,GRB10,NCK2,TEC 1.54 
axon guidance, axonogenesis, cell morphogenesis 




regulation of myeloid leukocyte differentiation, 
regulation of osteoclast differentiation 
APC,GNAS,TLR3 1.43 
insulin signalling pathway, regulation of cellular ketone 
metabolic process,regulation of fatty acid metabolic 
AGTR1,CBL,KRAS,PPARGC1A,PRKAA2,PRKAG2,RAPGEF1,SCAP 1.38 
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Key Terms Genes Score 
process 
apoptosis BIRC5,CASP9,EGLN3,KRAS,NTN1,NUAK2,OPA1,RPS3,STK4,YWHAB 1.37 
positive regulation of cellular component organization APC,CBL,NCK2,NTN1,PPARGC1A,ROBO1,SLIT2 1.35 
actin-dependent ATPase activity, calmodulin-binding, 
microfilament motor activity, myosin 
GAP43,KIF13B,MYH6,MYH9,MYO3A,SLC8A1,SYT1 1.32 
angiogenesis, blood vessel endothelial cell migration MYH9,ROBO1,SLIT2,STAB2,TGFBR2 1.32 
protein kinase binding ALS2,APC,BIRC5,DIAPH2,KIF13B,PRKAG2,RPS3,SUPT5H,TGFBR2,YWHAB 1.28 
positive regulation of leukocyte/lymphocyte activation & 
differentiation 
IL7R,NCK2,SART1,TGFBR2,TLR3,TLR8 1.25 
low-density lipoprotein binding COLEC12,LRP1B,STAB2 1.24 
nuclear lumen, nucleoplasm ABL1,BIRC5,BRCA2,CDC7,CTBP2,GLI3,GRHL1,GTF3C4,MYH6,PAPOLA,PPARG
C1A,PRKAA2,PRKAG2,PRPF8,RPA3,SUPT5H,TRIM27,WEE1,YWHAB 
1.23 
cytokinesis, interphase, tubulin binding ABL1,APC,ATG4A,BIRC5,BRCA2,CDC7,CNTROB,DIAPH2,FOXN3,GFI1B,HELLS,
MAP2K6,MYH9,SART1,SUPT5H,WEE1 
1.23 
cell morphogenesis involved in differentiation, cell 
motion 
ALS2,APC,GAP43,KAL1,MYH9,NCK2,NTN1,PTPRM,ROBO1,SLIT2 1.22 





embryonic development, striated muscle differentiation ALS2,BRCA2,GLI3,KRAS,MYH6,MYH9 1.14 
adherens junction, anchoring junction APBB1IP,APC,LIMA1,MYH6,MYH9,PTPRM 1.14 
chordate embryonic development ALS2,BRCA2,CHST11,GLI3,GNAS,MYH6,MYH9,TGFBR2 1.10 
hypertrophic cardiomyopathy (HCM) CACNA2D1,MYH6,PRKAA2,PRKAG2,SLC8A1 0.97 
regulation of lipid metabolic process AGTR1,PPARGC1A,PRKAA2,PRKAG2,SCAP 0.88 
Toll-Interleukin receptor, positive regulation of cytokine 
biosynthetic process 
TLR1,TLR3,TLR8,TNFRSF8 0.87 
domain:EGF-like LRP1B,SLIT2,STAB2 0.86 
fatty acid biosynthesis ELOVL5,PRKAA2,PRKAG2 0.84 
regulation of system process AGTR1,CELF2,GRM8,KRAS,MYH6,SLC8A1,TF 0.82 
negative regulation of cell proliferation APC,BRCA2,CTBP2,GLI3,NCK2,PTPRM,TGFBR2,TNFRSF8 0.80 
negative regulation of nucleobase, nucleoside, 
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Supplemental Table 25: DAVID functional clustering of the genes mapped by the SNPs selected by the ABACUS software on WES data 
Key Terms Genes Score 





serpin, serine-type endopeptidase inhibitor activity AMBP,CASP3,SERPINA11,SERPINB10,SERPINB2,SERPINF1,TRIAP1,TRIB3 2.46 










fatty-acid ligase activity, fatty acid metabolic process, 
long-chain-fatty-acid-CoA ligase activity 
ACSL3,ACSL5,FAAH,FASN,GGT5,PCSK9,PRKAB2,SGMS2,SLC27A6 1.84 



















carboxylic acid catabolic process AMDHD1,BCAT1,FAAH,KYNU 1.24 
cell fraction, insoluble fraction, membrane fraction ABCA4,ABCB11,ACSL3,ACSL5,AMBP,CGA,GIP,HEXB,ITPR3,KYNU,LRP1,MAP2K
1,MYO9B,PRKCQ,SLC17A4,SLIT3,STX2,TPPP 
1.21 
cofactor metabolic process AMBP,GGT5,KYNU,NARFL,PPCDC 1.15 
regulation of leukocyte activation, regulation of T cell 
activation 
CASP3,CD4,IL12B,IL31RA,PRKCQ 1.11 





adipocytokine signalling pathway ACSL3,ACSL5,PRKAB2,PRKCQ 1.07 
regulation of cellular response to stress AMBP,AXIN1,KLK8,TGFB2 1.00 
neuron differentiation, positive regulation of cell CASP3,CDON,DGKG,ERBB4,KLK8,MAP2K1,NEUROD1,ONECUT2,PCSK9,PRKCQ 0.99 
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Key Terms Genes Score 
migration, positive regulation of cell motion ,SALL1,SLIT3,TGFB2 
regulation of protein kinase activity, regulation of 
transferase activity 
AXIN1,CASP3,CD4,DGKG,DVL2,LRP1,MAP2K1,TGFB2,TRIB3 0.98 




positive regulation of cytokine biosynthetic process, 





ion transport ATP5A1,CACNA1D,ITPR3,KCNMB2,SCN10A,SLC10A6,SLC17A4,TRPC6 0.85 
positive regulation of protein modification process AXIN1,CD4,IL31RA,PLK1,PSMD3 0.85 




calcium channel, Vascular smooth muscle contraction ATP5A1,CACNA1D,ITPR3,KCNMB2,MAP2K1,PRKCQ,SCN10A,SLC10A6,SLC17A
4,TRPC6 
0.79 
negative regulation of growth CGA,GNG4,OSGIN1,TGFB2 0.77 
duplication ACTN2,AMBP,CD4,DGKG,GIP,PRKCQ 0.76 
cell proliferation BCAT1,ERBB4,KLK8,LRP1,MAP2K1,PLK1,SERPINF1,TGFB2 0.69 
negative regulation of response to stimulus, zymogen AMBP,CASP3,GGT5,HEXB,KLK8,PCSK9,SERPINF1,TGFB2 0.54 
chemical homeostasis, homeostatic process CASP3,ERBB4,HEXB,IL31RA,ITPR3,KCNMB2,NARFL,NEUROD1,NR5A2,PCSK9,T
RPC6 
0.52 
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Supplemental Table 26: Phenotype definitions. Table A: albuminuria- and eGFR based definitions. Table 




Normoalbuminuria AER <20 µg/min OR 
AER <30 mg/24 h OR 
ACR <2.5 mg/mmol for men  
ACR <3.5 for women 
Microalbuminuria At least 2 out of 3 consecutive measurements with: 
AER ≥20 AND <100 µg/min OR 
AER ≥30 AND <150 mg/24 hr OR 
ACR ≥2.5 AND <12.5 for men  
ACR ≥3.5 AND <17.5 for women. 
High microalbuminuria At least one measurement with: 
AER ≥100 AND <200 µg/min OR 
AER ≥150 AND <300 mg/24 hr OR 
ACR ≥12.5 AND <25 for men  
ACR ≥17.5 AND <35 for women 
Macroalbuminuria At least one measurement* with: 
AER ≥200 µg/min OR 
AER ≥300 mg/24 h OR 
ACR ≥25 mg/mmol for men  
ACR ≥35 for women  
 
*Due to study designs, in some studies at least two out of three consecutive 
measurements with the given thresholds were required. 
ESRD eGFR ≤15 ml/min/1.73m2 OR dialysis OR kidney transplantation.  
eGFR eGFR was estimated wither with the MDRD4 7 or CKD-EPI formula8, depending of the 
study. When IDMS-calibrated serum creatinine was used, the MDRD4 formula was 
multiplied by 175/186 65. 
CKD eGFR < 60 ml/min/1.73m2 
 
Table B: 
Phenotype name Cases Controls 
DKD microalbuminuria OR high microalbuminuria 
OR macroalbuminuria OR ESRD 
normoalbuminuria AND diabetes duration 
>15 years 
Early DKD microalbuminuria OR high microalbuminuria normoalbuminuria AND diabetes duration 
>15 years 
Late DKD macroalbuminuria OR ESRD normoalbuminuria AND diabetes duration 
>15 years 
ESRD vs. no DKD ESRD normoalbuminuria AND diabetes duration 
>15 years 
ESRD vs. non-ESRD ESRD patients with no ESRD AND diabetes 
duration >15 years 
CKD CKD (eGFR<60 ml/min/1.73m2) eGFR≥60 ml/min/1.73m2 AND diabetes 
duration >15 years 
CKD+DKD (eGFR < 45 ml/min OR ESRD/1.73m2) AND 
(High micro OR Macro OR ESRD) 
eGFR ≥ 60 ml/min/1.73m2 AND normo-
albuminuria AND diabetes duration >15 
years 
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Supplemental Table 27: Membership of the GENIE Consortium 
FinnDiane, 
Finland: 
Niina Sandholm1,2,3, Carol Forsblom1,2, Valma Harjutsalo1,2,4, Ville-Petteri Mäkinen1,2, 4,6, 
Aila J Ahola1,2, Emma Dahlström1,2, Daniel Gordin1,2, Outi Heikkilä1,2, Kustaa Hietala1,7, 
Janne Kytö1,7, Markku Lehto1,2, Raija Lithovius1,2, Nicolae Mircea Panduru1,8, Maija 
Parkkonen1,2, Milla Rosengård-Bärlund1,2, Markku Saraheimo1,2, Jenny Söderlund1,2, Aino 
Soro-Paavonen1,2, Anna Syreeni1,2, Lena M Thorn1,2, Nina Tolonen1,2, Johan Wadén1,2, Per-
Henrik Groop1,2,9 
Belfast, UK: Amy Jayne McKnight10, Gareth J. McKay10, Alexander P. Maxwell10,11 
Boston, MA, 
USA: 
Rany M. Salem12,13,14, Tamara Isakova15,16, Cameron Palmer12,13, Candace Guiducci12, 
Andrew Taylor12,17, Daniel B. Mirel12, Winfred W. Williams14,17, Joel N. Hirschhorn12,13,14, 
Jose C. Florez12,14,17 
Dublin, 
Ireland: 
Eoin P. Brennan18,19, Denise M. Sadlier18,19, Finian Martin18,19, Catherine Godson18,19 
Affiliations: 
 
1. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland  
2. Department of Medicine, Division of Nephrology, Helsinki University Central 
Hospital, Helsinki, Finland  
3. Department of Biomedical Engineering and Computational Science, Aalto 
University, Espoo, Finland  
4. Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, 
Finland. 
5. Department of Integrative Biology and Physiology, University of California Los 
Angeles, United States 
6. South Australian Health and Medical Research Institute, Adelaide, Australia 
7. Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, 
Finland. 
8. Chair of pathophysiology, 2nd clinical Department, "Carol Davila" University of 
Medicine and Pharmacy, Bucharest, Romania. 
9. Baker IDI Heart and Diabetes Institute, Melbourne, Australia. 
10. Nephrology Research, Centre for Public Health, Queen’s University of Belfast, 
Belfast, UK. 
11. Regional Nephrology Unit, Level 11, Tower Block, Belfast City Hospital, Belfast, UK. 
12. Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA. 
13. Endocrine Research Unit, Department of Endocrinology, Children’s Hospital, 
Boston, MA, USA. 
14. Department of Medicine, Harvard Medical School, Boston, MA, USA. 
15. Division of Nephrology and Hypertension, University of Miami, Miami, Florida, USA 
16. Center for Translational Metabolism and Health - Institute for Public Health and 
Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 
USA 
17. Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, 
USA. 
18. Diabetes Research Centre, Conway Institute, School of Medicine and Medical 
Sciences, University College Dublin, Dublin, Ireland. 
19. Mater Misericordiae Hospital, Dublin, Ireland. 
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Supplemental Table 28: List of the FinnDiane centers and participating physicians and nurses.  
FinnDiane Study Centers Physicians and nurses 
Anjalankoski Health Center  S. Koivula, T. Uggeldahl 
Central Finland Central Hospital, Jyväskylä T. Forslund, A. Halonen, A. Koistinen, P. Koskiaho, M. Laukkanen, J. Saltevo, M. Tiihonen 
Central Hospital of Åland Islands, Mariehamn M. Forsen, H. Granlund, A-C. Jonsson, B. Nyroos 
Central Hospital of Kanta-Häme, Hämeenlinna P. Kinnunen, A. Orvola, T. Salonen, A. Vähänen 
Central Hospital of Länsi-Pohja, Kemi H. Laukkanen, P. Nyländen, A. Sademies 
Central Ostrabothnian Hospital District, Kokkola S. Anderson, B. Asplund, U. Byskata, M. Kuusela, P. Liedes, T. Virkkala 
City of Espoo Health Centre:  
-Espoonlahti A. Nikkola, E. Ritola 
-Samaria E. Oukko-Ruponen, T. Virtanen 
-Tapiola M. Niska, H. Saarinen 
-Viherlaakso  A. Lyytinen 
City of Helsinki Health Centre:  
-Puistola H. Kari, T. Simonen 
-Suutarila A. Kaprio, J. Kärkkäinen, B. Rantaeskola 
-Töölö J. Haaga, P. Kääriäinen, A-L. Pietiläinen 
City of Hyvinkää Health Centre S. Klemetti, T. Nyandoto, E. Rontu, S. Satuli-Autere 
City of Vantaa Health Centre:  
-Korso  R. Toivonen, H. Virtanen 
-Länsimäki R. Ahonen, M. Ivaska-Suomela, A. Jauhiainen 
-Martinlaakso M. Laine, T. Pellonpää, R. Puranen 
-Myyrmäki A. Airas, J. Laakso, K. Rautavaara 
-Rekola  M. Erola, E. Jatkola 
-Tikkurila R. Lönnblad, A. Malm, J. Mäkelä, E. Rautamo 
Heinola Health Centre P. Hentunen, J. Lagerstam 
Abdominal Center Nephrology, University of Helsinki 
and Helsinki University Hospital, Helsinki, Finland 
M. Feodoroff, C. Forsblom, D. Gordin, PH Groop, V. Harjutsalo, S. Hägg-Holmberg, K. Hietala, M. 
Kallio, R. Lithovious, M. Parkkonen, M. Rahkonen, M. Rosengård-Bärlund, A.-R. Salonen, L. 
Salovaara, A. Sandelin, M. Saraheimo, T. Soppela, A. Soro-Paavonen, L. Thorn, N. Tolonen, J. 
Tuomikangas, J. Wadén,  
Ophthalmology, University of Helsinki and Helsinki P.Summanen 
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FinnDiane Study Centers Physicians and nurses 
University Hospital, Helsinki, Finland 
Herttoniemi Hospital, Helsinki V. Sipilä 
Hospital of Lounais-Häme, Forssa T. Kalliomäki, J. Koskelainen, R. Nikkanen, N. Savolainen, H. Sulonen, E. Valtonen 
Hyvinkää Hospital A. Hämäläinen, L. Norvio 
Iisalmi Hospital E. Toivanen 
Jokilaakso Hospital, Jämsä A. Parta, I. Pirttiniemi 
Jorvi Hospital, Helsinki University Central Hospital S. Aranko, S. Ervasti, R. Kauppinen-Mäkelin, A. Kuusisto, T. Leppälä, K. Nikkilä, L. Pekkonen 
Jyväskylä Health Centre, Kyllö K. Nuorva, M. Tiihonen 
Kainuu Central Hospital, Kajaani S. Jokelainen, P. Kemppainen, A-M. Mankinen, M. Sankari 
Kerava Health Centre H. Stuckey, P. Suominen 
Kirkkonummi Health Centre A. Lappalainen, M. Liimatainen, J. Santaholma 
Kivelä Hospital, Helsinki A. Aimolahti, E. Huovinen 
Koskela Hospital, Helsinki V. Ilkka, M. Lehtimäki 
Kotka Heath Centre E. Pälikkö-Kontinen, A. Vanhanen 
Kouvola Health Centre E. Koskinen, T. Siitonen 
Kuopio University Hospital 
E. Huttunen, R. Ikäheimo, P. Karhapää, P. Kekäläinen, T. Lakka, M. Laakso, E. Lampainen, L. 
Moilanen, L. Niskanen, U. Tuovinen, I. Vauhkonen, E. Voutilainen 
Kuusamo Health Centre E. Isopoussu, T. Kääriäinen 
Kuusankoski Hospital E. Kilkki, I. Koskinen, L. Riihelä 
Laakso Hospital, Helsinki T. Meriläinen, P. Poukka, R. Savolainen, N. Uhlenius 
Lahti City Hospital A. Mäkelä, M. Tanner 
Lapland Central Hospital, Rovaniemi L. Hyvärinen, S. Severinkangas, T. Tulokas 
Lappeenranta Health Centre P. Linkola, I. Pulli 
Lohja Hospital T. Granlund, M. Saari, T. Salonen 
Loimaa Health Centre  P. Eloranta, A. Mäkelä 
Länsi-Uusimaa Hospital, Tammisaari I-M. Jousmaa, J. Rinne 
Malmi Hospital, Helsinki H. Lanki, S. Moilanen, M. Tilly-Kiesi 
Mikkeli Central Hospital A. Gynther, R. Manninen, P. Nironen, M. Salminen, T. Vänttinen 
Mänttä Regional Hospital A-M. Hänninen, I. Pirttiniemi 
North Karelian Hospital, Joensuu U-M. Henttula, P. Kekäläinen, M. Pietarinen, A. Rissanen, M. Voutilainen 
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FinnDiane Study Centers Physicians and nurses 
Nurmijärvi Health Centre A. Burgos, K. Urtamo 
Oulankangas Hospital, Oulainen E. Jokelainen, P-L. Jylkkä, E. Kaarlela, J. Vuolaspuro 
Oulu Health Centre L. Hiltunen, R. Häkkinen, S. Keinänen-Kiukaanniemi 
Oulu University Hospital R. Ikäheimo 
Päijät-Häme Central Hospital H. Haapamäki, A. Helanterä, S. Hämäläinen, V. Ilvesmäki, H. Miettinen 
Palokka Health Centre P. Sopanen, L. Welling 
Pieksämäki Hospital V. Javtsenko, M. Tamminen 
Pietarsaari Hospital M-L. Holmbäck, B. Isomaa, L. Sarelin 
Pori City Hospital P. Ahonen, P. Merensalo, K. Sävelä 
Porvoo Hospital M. Kallio, B. Rask, S. Rämö 
Raahe Hospital A. Holma, M. Honkala, A. Tuomivaara, R. Vainionpää 
Rauma Hospital K. Laine, K. Saarinen, T. Salminen 
Riihimäki Hospital P. Aalto, E. Immonen, L. Juurinen 
Salo Hospital A. Alanko, J. Lapinleimu, P. Rautio, M. Virtanen 
Satakunta Central Hospital, Pori M. Asola, M. Juhola, P. Kunelius, M-L. Lahdenmäki, P. Pääkkönen, M. Rautavirta 
Savonlinna Central Hospital  E. Korpi-Hyövälti, T. Latvala, E. Leijala 
South Karelia Central Hospital, Lappeenranta T. Ensala, E. Hussi, R. Härkönen, U. Nyholm, J. Toivanen 
Tampere Health Centre 
P. Alarotu, L. Calonius, S. Gummerus, M. Helin, T. Kaitala, H. Kirkkopelto-Jokinen, E. Kujansuu, T. 
Niskanen,  A. Vaden, T. Vatanen 
Tampere University Hospital 
I. Ala-Houhala, T. Kuningas, P. Lampinen, M. Määttä, H. Oksala, T. Oksanen, K. Salonen, H. 
Tauriainen, S. Tulokas 
Tiirismaa Health Centre, Hollola T. Kivelä, L, Petlin, L. Savolainen 
Turku Health Centre I. Hämäläinen, H. Virtamo, M. Vähätalo 
Turku University Central Hospital K. Breitholz, R. Eskola, K. Metsärinne, U. Pietilä, P. Saarinen, R. Tuominen, S. Äyräpää 
Vaajakoski Health Centre K. Mäkinen, P. Sopanen 
Vaasa Central Hospital S. Bergkulla, U. Hautamäki, V-A. Myllyniemi, I. Rusk 
Valkeakoski Regional Hospital T. Immonen, S. Ojanen, M. Rautiainen, E. Valtonen, H. Ylönen 
Vammala Regional Hospital  I. Isomäki, R. Kroneld, M. Tapiolinna-Mäkelä 
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Supplemental Table 29: Membership of the SUMMIT Consortium 
Partner Name Position 
1 Michael Mark Coordinator, WP6 leader 
Boehringer-Ingelheim Markus Albertini Project manager 
Ingelheim, Germany Carine Boustany Chronic Kidney Disease, Head of Lab 
  Alexander Ehlgen Transmed 
  Martin Gerl Biomarker & Bioanlysis, Groupleader 
  Jochen Huber In vivo Scientist CMDR, Head of Lab 
  Corinna Schölch Biomarker & Bioanlysis, Head of Lab 
  Heike Zimdahl-Gelling Pharmacogenomics, Head of Lab 
      
2 Leif Groop 
Prof. Endocrinology; Coordinator Managing entity IMI-
JU; PI; WP1 and WP6 leader 
Lund University Elisabet Agardh Prof. Ophthalmology 
Clinical Research 
Centre Emma Ahlqvist Postdoc 
Malmö, Sweden Tord Ajanki Communication strategist 
  Nibal Al Maghrabi Research nurse 
  Peter Almgren Biostatistician 
  Jan Apelqvist Diabetologist 
  Eva Bengtsson Assis. Prof. Cardiovascular research 
  Lisa Berglund Postdoc 
  Harry Björckbacka Assis. Prof. Cardiovascular research 
  Ulrika Blom-Nilsson LUDC administrator 
  Mattias Borell Website, server management 
  Agneta Burström Research nurse 
  Corrado Cilio Assoc. Prof. Cellular autoimmunity 
  Magnus Cinthio 
Assist. Prof. Electrical Measurements, Lund Technical 
University 
  Karl Dreja Nephrologist 
  Pontus Dunér Postdoc Exp. Cardiovasc. Research 
  Daniel Engelbertsen PhD student Exp. Cardiovasc. Research 
  Joao Fadista Postdoc 
  Maria Gomez Assoc. Prof. Cardiovascular disease, WP4 co-leader 
  Isabel Goncalves Assis. Prof. Cardiovascular research 
  Bo Hedblad Prof. Cardiovascular epidemiology 
  Anna Hultgårdh Prof. Vessel Wall Biology 
  Martin E. Johansson Pathologist 
  Cecilia Kennbäck Laboratory Engineer 
  Jasmina Kravic Database manager 
  Claes Ladenvall Genetic statistician 
  Åke Lernmark Prof. Type 1 diabetes and celiac disease 
  Eero Lindholm Physician, Researcher Diabetic Complications 
  Charlotte Ling Assist. Prof. Epigenetics 
  Holger Luthman Prof. Medical genetics 
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Partner Name Position 
  Olle Melander Assoc. Prof. Hypertension and cardiovascular disease 
  Malin Neptin Biomedical analyst 
  Jan Nilsson 
Prof. Experimental Cardiovascular research, WP3 
leader 
  Peter Nilsson Prof. Internal medicine 
  Tobias Nilsson 




Fredriksson Prof. Cardiovascular research 
  Marju Orho-Melander Prof. Genetic epidemiology 
  Emilia Ottoson-Laakso PhD student 
  Annie Persson Research nurse 
  Margaretha Persson Laboratory Engineer 
  Mats-Åke Persson Database manager 
  Jacqueline Postma Project manager 
  Elisabeth Pranter Research nurse 
  Sara Rattik PhD student Exp. Cardiovasc. Research 
  Gunnar Sterner Chief physician Internal Medicine Research Unit 
  Lilian Tindberg Research nurse 
  Maria Wigren Postdoc Exp. Cardiovasc. Research 
  Anna Zetterqvist PhD student 
  Mikael Åkerlund Postdoc 
  Gerd Östling Laboratory Engineer 
      
3 Timo Kanninen Technical director; PI 
Biocomputing 
Platforms  Anni Ahonen-Bishopp Software development manager 
(BC Platforms) Anita Eliasson Financial and administrative director 
Espoo, Finland Timo Herrala System (server) specialist 
  Päivi Tikka-Kleemola Service manager 
      
4 Anders Hamsten 
Prof. Cardiovascular disease; Atherosclerosis Research 
Unit; PI 
Karolinska Institute Christer Betsholtz Prof. Vascular biology 
Stockholm, Sweden Ami Björkholm Administrator 
  Ulf de Faire Professor emeritus Cardiovascular epidemiology 
  Fariba Foroogh Research engineer 
  Guillem Genové Scientist 
  Karl Gertow Research Assist. Prof. Cardiovascular genetics 
  Bruna Gigante Assoc. Professor Cardiovascular epidemiology 
  Bing He Postdoc 
  Karin Leander Assoc. Professor Cardiovascular epidemiology 
  Olga McLeod Postdoc 
  Maria Nastase-Mannila Postdoc 
  Jaako Patrakka Postdoc 
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Partner Name Position 
  Angela Silveira Assoc. Prof. Cardiovascular genetics 
  Rona Strawbridge Postdoc 
  Karl Tryggvason Prof. Medical Chemistry 
  Max Vikström Statistician 
  John Öhrvik Professor 
  Anne-May Österholm  Postdoc 
      
5 Barbara Thorand Nutritional scientist, epidemiologist 
Helmholtz Centre Christian Gieger Statistician 
Munich, Germany Harald Grallert Biologist 
  Tonia Ludwig Statistician 
  Barbara Nitz Scientist 
  Andrea Schneider Data manager 
  Rui Wang-Sattler Scientist 
  Astrid Zierer Statistician 
      
6 Giuseppe Remuzzi Institute director; PI 
Mario Negri Institute 
for  Ariela Benigni Head of department Molecular Medicine 
Pharmacological 
Research Roberta Donadelli Scientist 
  Maria Domenica Lesti Researcher 
Bergamo, Italy Marina Noris 
Head Laboratory Immunology and genetics of 
transplantation and rare diseases 
  Norberto Perico Senior scientist 
  Annalisa Perna Biostatistician 
  Rossella Piras Postdoc 
  Piero Ruggenenti 
Head of department Renal medicine, Assist. Prof. 
Nephrology and dialysis 
  Erica Rurali Postdoc 
      
7 
David Dunger (att: 
Jane Horsford) Prof. Paediatrics; PI 
University of 
Cambridge Ludo Chassin Senior Data Manager 
UK Neil Dalton, London Clinical biochemistry 
  John Deanfield, London Paediatric cardiology 
  Jane Horsford PA to Prof. Dunger 
  Clare Rice Operations manager/financial contact 
  James Rudd Cardiovascular imaging 
  Neil Walker Head Data services 
  Karen Whitehead Technician 
  Max Wong Postdoc 
      
8 Helen Colhoun 
Prof. Public health and epidemiology; PI; Vice 
coordinator Managing entity; WP2 leader 
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Partner Name Position 
  Fiona Adams   
University of Dundee Tahira Akbar PA to Helen Colhoun 
Scotland Jill Belch Prof. Vasucular disease 
  Harshal Deshmukh PhD student 
  Fiona Dove   
  Angela Ellingford 
NHS Tayside Diabetic Retinopathy Screening 
Programme manager 
  Bassam Farran Statistician 
  Mike Ferguson 
Dean of research Biological chemistry and drug 
discovery 
  Gary Henderson   
  Graeme Houston Consultant radiologist/senior lecturer 
  Faisel Khan 
Reader, Vascular & Inflammatory Diseases Research 
Unit 
  Graham Leese Consultant diabetologist/reader 
  Yiyuan Liu PhD student 
  Shona Livingstone Senior statistician 
  Helen Looker Epidemiologist 
  Margaret McCann Project assistant  
  Stuart McGurnaghan Lead data programmer 
  Andrew Morris Prof. Diabetic medicine 
  David Newton   
  Colin Palmer Prof. Pharmacogenomics 
  Ewan Pearson Consultant diabetologist/senior lecturer 
  Gillian Reekie Research Nurse 
  Natalie Smith Research Nurse 
      
9 Angela Shore Prof. Cardiovascular Science, PI 
Peninsula Medical 
School Kuni Aizawa Postdoc 
Exeter, UK Claire Ball Research nurse 
  Nick Bellenger Cardiologist 
  Francesco Casanova Associate Research Fellow Vascular medicine 
  Tim Frayling Prof. Genetics 
  Phil Gates Senior lecturer Cardiovascular science 
  Kim Gooding Postdoc Vascular medicine 
  Andrew Hatttersley Prof. Molecular medicine 
  Roland Ling Consultant opthalmologist 
  David Mawson Research technician 
  Robin Shandas Prof. Bioengineering (Colorado) 
  David Strain Stroke physician, clinical lecturer 
  Clare Thorn Postdoc Vascular medicine 
      
10 Ulf Smith Prof. ; PI 
University of Ann Hammarstedt Researcher Molecular and clinical medicine 
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Partner Name Position 
Gothenburg 
Sweden Hans Häring Prof. University of Tübingen 
  Oluf Pedersen Prof. Steno Centre, Copenhagen 
  Georgio Sesti Prof. Universtiy of Catanzaro 
      
11 Per-Henrik Groop Prof. Diabetes genetics; PI 
  Emma Fagerholm PhD student, genetics 
Folkhälsan Carol Forsblom Clinical coordinator 
Helsinki, Finland Valma Harjutsalo   
  Maikki Parkkonen Laboratory manager 
  Niina Sandholm DSc(PhD); GWAS and bioinformatics 
  Nina Tolonen MD PhD 
  Iiro Toppila BSc, bioinformatician 
  Erkka Valo MSc, bioinformatician 
      
12 Veikko Salomaa Prof. Epidemiology; PI; deputy leader WP2 
The National Institute 
for Health and 
Welfare Aki Havulinna DSc. (tech), statistician 
Helsinki, Finland Kati Kristiansson Postdoc 
  Pia Okamo THL press officer 
  Tomi Peltola   
  Markus Perola Professor 
  Arto Pietilä Statistician 
  Samuli Ripatti Professor, Statistics 
  Marketta Taimi Research assistant 
      
13 Seppo Ylä-Herttuala Prof.; PI; WP4 leader 
University of Eastern 
Finland Mohan Babu PhD student 
Kuopio, Finland Marike Dijkstra PhD student 
  Erika Gurzeler PhD student 
  Jenni Huusko PhD student 
  Ivana Kholová Postdoc 
  Markku Laakso Prof.  
  Mari Merentie PhD student 
  Marja Poikolainen PA Prof Ylä-Herttuala 
      
14 Mark McCarthy 
Prof. Human type 2 diabetes; Oxford Centre for 
Diabetes, Endocrinology and Metabolism; Wellcome 
Trust Centre for Human Genetics; PI; deputy leader 
WP1 
University of Oxford Chris Groves Technical staff 
UK Thorhildur Juliusdottir PhD student 
  Fredrik Karpe PI OCDEM 
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Partner Name Position 
  Vasiliki Lagou Postdoc 
  Andrew Morris 
Wellcome Trust Senior Fellow; Bioinformatics and 
statistical genetics 
  Will Rayner Database manager 
  Neil Robertson Informatics 
  Natalie van Zuydam Postdoc 
      
15 Claudio Cobelli Prof. ; PI; WP5 leader 
University of Padova Barbara Di Camillo Assist. Prof.  
Italy Francesca Finotello PhD student 
  Francesco Sambo Postdoctoral fellow 
  Gianna Toffolo Prof.  
  Emanuele Trifoglio PhD student 
      
16 Riccardo Bellazzi Prof. Bioengineering; PI; deputy leader WP5 
  Nicola Barbarini Postdoctoral fellow 
University of Pavia Mauro Bucalo Software engineer 
Italy Christiana Larizza Assist. Prof.  
  Paolo Magni Assoc. Prof. 
  Alberto Malovini Postdoctoral fellow 
  Simone Marini Postdoctoral fellow 
  Francesca Mulas Postdoctoral fellow 
  Silvana Quaglini Prof. 
  Lucia Sacchi Assist. Prof.  
  Francesca Vitali   
      
17 Ele Ferrannini Prof. Medicine; PI 
  Beatrice Boldrini Postdoctoral fellow 
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SUPPLEMENTAL FIGURES 
Supplemental Figure 1: Schematic picture of the study plan. In the GWAS setting, the stage 1 included T1D 
patients from the FinnDiane, EURODIAB, SDR, and Cambridge studies. Stage 1 GWAS meta-analysis results 
were used for evaluation of the previously reported loci, analysis of genetic risk scores, LD score regression, 
and for the pathway analyses. Stage 2 included patients from the UK-ROI, GoKinD US, French-Danish effort, 
DCCT/EDIC, and Joslin studies. Stage 3 replication consisted of additional T1D FinnDiane patients not part of 
the FinnDiane GWAS. Whole exome sequencing (WES) included patients from the FinnDiane, SDR, and Steno 
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Supplemental Figure 2: Manhattan and QQ-plots for the seven studied phenotype definitions. Manhattan and 
QQ-plots of the seven studied case-control phenotype definitions: A) Combined DKD (cases with micro- or 
macroalbuminuria or ESRD vs. controls with normal AER); B) Late DKD (cases with macroalbuminuria or ESRD vs. normal 
AER); C) ESRD vs. no DKD (cases with ESRD vs. controls with normal AER); D) ESRD vs. non-ESRD (cases with ESRD vs. 
everyone else); E) Early DKD (cases with microalbuminuria vs. controls with normal AER); F) CKD (cases with CKD (eGFR ≤ 
60 ml/min) vs. controls without CKD (eGFR > 60 ml/min); G) CKD+DKD (cases with severe CKD (eGFR ≤ 45 ml/min) and 
microalbuminuria or worse vs. controls with normal AER and no CKD (eGFR > 60 ml/min). 
A) Combined DKD 
 
B) Late DKD 
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C) ESRD vs. no DKD 
 
D) ESRD vs. non-ESRD 
 
E) Early DKD 
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G) CKD + DKD 
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Supplemental Figure 3: LocusZoom and Forest plots of the top loci. A) rs72809865 for DKD. B) rs61277444 for 
ESRD versus normal AER. C) rs7562121 for ESRD versus non-ESRD. D) rs1989248 for CKD+DKD. 
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Supplemental Figure 4: P-value distribution of association at the previously reported loci for DKD or CKD 
in the general population. 
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Supplemental Figure 5: Association at previously reported loci plotted by the previously reported A) p-
values and by B) Z-scores. 
 
Page 127 of 145
ScholarOne support: 888-503-1050






























































Supplementary information: Genome-wide dissection of diabetic kidney disease 
69 
Supplemental Figure 6: Genome-wide comparison of the association results for the seven DKD traits, 
evaluated with LD score regression, shows high correlation between the DKD traits. Even though the 




Page 128 of 145
ScholarOne support: 888-503-1050






























































Supplementary information: Genome-wide dissection of diabetic kidney disease 
70 
Supplemental Figure 7: KEGG pentose and glucoronate interconversions pathway with the red boxes 
indicating the genes flagged with MAGENTA enrichment analysis on the DKD phenotype. The Glucuronate 
sub-pathway (KEGG module M00014) is highlighted with pink background. P-value for enrichment of the glucoronate 
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Supplemental Figure 8: WES QQ-plots of the p-value distribution of associations with ‘Late DKD’ and 
‘ESRD vs. no DKD’ using the score test. A and B: DKD. C and D: ESRD. A and C: all SNPs. B and D: SNPs by MAF. 
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Supplemental Figure 9: WES QQ-plots for ‘Late DKD’ for different masks using SKAT-O. 
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Supplemental Figure 10: WES QQ-plots for ‘ESRD vs. no DKD’ for different masks using SKAT-O. 
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Supplemental Figure 11: Top 20 associations for ‘Late DKD’ for the three gene based tests; VT, SKAT-O 
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Supplemental Figure 12: Top 20 associations for ‘ESRD vs. no DKD’ for the three gene based tests; VT, 
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Supplemental Figure 13: Statistical power to detect association at the WES with exome-wide statistical 
significance (p<9×10-8) for ‘Late DKD’ setting (panels A and C) and for the ‘ESRD vs. no DKD’ comparison 
(panels B and D). The top panels show the statistical power for the effect allele frequency range from 0 to 1. The 
bottom panels show the statistical power for the effect allele frequency range from 0 to 10%.  
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